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Highlights 
 Targeting of the transferrin receptor is one of the most efficient ways of obtaining brain drug delivery. 
 Despite decades of development, very little clinical progression has been made, although few clinical 
trials are beginning to emerge. 
 New innovations in terms of modifications of the antibody binding mode has yielded impressive leaps 
forward in our understanding of the transport process. 
 Many parameters in the transferrin receptor-mediated transport across the blood-brain barrier are still 
poorly understood. 
 Increased understanding of factors like intracellular sorting and subsequent long-term brain retention 
of TfR-targeted drug delivery systems is needed to fulfill the ambition of clinical use. 
 
Abstract 
Obtaining efficient drug delivery to the brain remains the biggest challenge for the development of therapeutics 
to treat diseases of the central nervous system. The main obstacle is the blood-brain barrier (BBB), which 
impedes the entrance of most molecules present in the systemic circulation, especially large molecule drugs 
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and nanomedicines. To overcome this obstacle, targeting strategies binding to nutrient receptors present at the 
luminal membrane of the BBB are frequently employed. Amongst the numerous potential targets at the BBB, 
the transferrin receptor (TfR) remains the most common target used to ensure sufficient drug delivery to the 
brain. In this review, we provide a full account on the use of the TfR as a target for brain drug delivery by 
describing the function of the TfR in the BBB, the historical background of its use in drug delivery, and the 
most recent evidence suggesting TfR-targeted medicines to be efficient for brain drug delivery with a clear 
clinical potential. 
 
Statement of significance 
Targeting of the TfR remains the most important tool to improve brain drug delivery. The recent years has 
seen both technological advancements as well as introduction of the strategy to clinical trials. This review 
provides the first full account of the field of TfR-targeted brain drug delivery systems to be published, 
including a description of the relevance of TfR-targeting in relation to antibody-based medicines and large 
nanocarriers used to treat brain diseases. 
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1. Introduction 
Millions worldwide suffer from neurological disorders, and even more will be affected by e.g. Alzheimer’s 
and Parkinson’s disease, and cerebrovascular diseases in the coming decades (Murray et al., 2012; Whiteford 
et al., 2015). The possibilities for treatment of neurological diseases are hampered because drug delivery to 
the brain is hindered by the blood-brain barrier (BBB). The BBB functions to regulate the fluxes of molecules 
between the systemic circulation and the brain (Abbott, 2013). Development of successful strategies to bypass 
the integrity of the BBB is thus pivotal to obtain tools that will allow for treatment of diseases of the central 
nervous system (CNS). To develop such bypassing strategies, it is also of great importance to understand the 
morphological and physiological features that characterize the BBB. A promising strategy is to target CNS-
active drugs towards BBB-associated carrier and receptor proteins, among which a targeting approach against 
the transferrin receptor (TfR) that is expressed by brain capillary endothelial cells (BCECs) is the most widely 
used (Johnsen and Moos, 2016). 
In this review, the current knowledge on the role of the TfR in brain iron uptake is delineated. This is 
followed by full coverage of the functions of the TfR and its ligands together with a thorough summary of 
studies investigating the delivery of TfR-targeted antibodies and nanomedicines to the brain parenchyma. The 
challenges of the TfR-targeting strategy are discussed with emphasis on the possibilities to improve this type 
of brain drug delivery to become the brain medicines of the future.     
 
1.1. The blood-brain barrier 
The BBB is located within the microvasculature of the brain, and it regulates passage of molecules from the 
blood to the brain (Burkhart et al., 2014). The BCECs of the brain’s microvasculature form the BBB (Abbott, 
2013), while pericytes and astrocytes support the BCECs barrier function during embryonic formation and 
maintenance of the BBB (Figure 1)(Armulik et al., 2010; Daneman et al., 2010b; Sengillo et al., 2012). 
Pericytes are embedded in the shared basement membrane on the abluminal side of the BCECs (Armulik et 
al., 2011), and they contribute to the tightness of the BBB by decreasing transcytosis and by inducing 
polarization of astrocyte end-feet (Armulik et al., 2010; Daneman et al., 2010a). The end-feet of astrocytes 
cover a substantial part of the abluminal side of the BCECs and the pericytes (Abbott et al., 2006). These 
perivascular astrocytes play a significant role in intercellular tightening of the BBB and regulation of polarized 
expression of BCEC transporters (Abbott et al., 2006; Wolburg et al., 2009).   
 
1.2. Brain capillary endothelial cells form the blood-brain barrier 
The BCECs differ from the peripheral endothelial cells by having less endocytic vesicles, specialized 
transcellular transport systems, very low paracellular passage, and by lacking fenestrations (Abbott et al., 
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2010). The BCECs also express efflux transporters e.g. P-glycoprotein (P-gp) and breast cancer related protein 
(BCRP), which reduce the entry of amphiphilic drugs by carrier-mediated efflux of some of these drugs from 
the BCECs to the brain (Abbott et al., 2010). Altogether, the BCECs form a very tight barrier, which is mainly 
due to a restricted paracellular and transcellular passage (Burkhart et al., 2014). 
In the junctions between the BCECs, three groups of junctional proteins are expressed. The first group 
is the tight junctions (TJs), which are the limiting factor for the paracellular passage since they only enable 
passage of very small hydrophilic molecules (Haseloff et al., 2015)(Figure 1). The TJ proteins include claudin 
1, 3 and 5, which are connected to the BCECs cytoskeleton via the membrane-associated zonula occludens 
proteins 1-3 (ZO 1-3)(Nitta et al., 2003; Wolburg et al., 2003). Furthermore, in addition to the TJs are the tight 
junction-associated marvel proteins, occludin and tricellulin (Hirase et al., 1997; Mariano et al., 2013). The 
second group is the adherence junction (AJs) proteins, which include vascular endothelial cadherin (VE-
cadherin), catenins, and platelet endothelial cell adhesion molecules (PECAM)(Wolburg and Lippoldt, 2002). 
The AJs are important for interconnection of the BCECs, hence giving structural tissue support (Abbott et al., 
2010). The third group is denoted by the junctional adhesion molecules (JAMs)(Abbott et al., 2010). The 
function of the JAMs is not fully uncovered, but they seem to have a role in cell adhesion of leukocytes 
(Burkhart et al., 2014). The adherence junctions, ZO 1-3 and JAMs does not directly take part in limiting the 
paracellular passage but support the structure in forming a tight barrier (Haseloff et al., 2015). The limited 
paracellular passage at the BBB is mainly obtained by the presence of claudins and occludins, with claudin 5 
being the most important protein for maintaining the tight BBB (Haseloff et al., 2015). 
 
1.3. Transport mechanisms at the blood-brain barrier  
The transcellular passage through the BCECs (Figure 2) can take place either via 1) cell entry by leukocytes; 
2) carrier-mediated influx of e.g. glucose by glucose transporter 1 (GLUT-1), amino acids by e.g. the L-type 
amino acid transporter 1 (LAT-1) and small peptides by e.g. organic anion-transporting peptide-B (OATP-B); 
3) paracellular passage of small hydrophobic molecules; 4) adsorption-mediated transcytosis of e.g. albumin 
and cationized molecules; 5) passive diffusion of lipid soluble, non-polar solutes, including CO2 and O2; and 
5) receptor-mediated transcytosis of e.g. insulin by the insulin receptor and Tf by the TfR (Abbott, 2013; 
Abbott et al., 2006; Begley and Brightman, 2003). These transport systems have all been explored for their 
use as targets for drug delivery to the brain (Abbott et al., 2010; Burkhart et al., 2014; Lichota et al., 2010). 
Among these, the receptor-mediated transport route is the focus of this review. The purpose of targeting the 
BBB receptors is to use ligands or monoclonal antibodies as ferrying molecules, thereby exploiting the ability 
of these molecules to bind to receptors and induce transport of the drug into the brain. To secure exclusive 
uptake in the brain following intravascular administration, a drug-bearing ligand needs its target receptor to be 
either upregulated at the BBB or limited to be expressed by the BCECs. 
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A plethora of studies have explored the use of BBB receptors and their ligands for developing 
strategies to bypass the BBB (see e.g. Table 4 in Abbott et al. (2010)(Abbott et al., 2010)). The TfR is of high 
interest due to its exclusive expression in the BCECs compared to other types of endothelial cells in the 
periphery (Jefferies et al., 1984). Although the theory of using BCECs receptors for drug delivery is promising, 
many obstacles have been encountered in the process: 1) The endogenous receptor ligand can in some cases 
outcompete binding of the drug-bearing ligand (Lichota et al., 2010), 2) The affinity of the drug-bearing ligand 
to the receptor can also influence the uptake and thereby form either too weak or too strong bindings to the 
receptors to undergo transcellular transport (Burkhart et al., 2014; Yu et al., 2011), 3) The drug-bearing ligand 
can be a substrate for the efflux transporter and be transported out of the BCECs after being internalized in the 
cell (Begley, 2004), 4) The endothelial glycocalyx denote an obstacle for the drug bearing ligand by filtering 
molecules before they reach the BCECs luminal cell membrane (Brightman and Kaya, 2000), and 5) The 
BCECs basement membrane can hinder transport from the BCECs and into the brain parenchyma (Muldoon 
et al., 1999). These obstacles need to be overcome for a brain drug delivery strategy to become successful, and 
amongst the different strategies that are known and have been studied, targeting TfRs at the BBB represents 
one of the most relevant and efficient ones (in addition to e.g. the insulin receptor (Giugliani et al., 2018; 
Pardridge et al., 2018a)). 
 
2. Iron uptake and metabolism in the brain 
To evaluate the potential of TfR as a target for brain drug delivery a detailed understanding of the process of 
brain iron uptake via the TfR is necessary. Such a detailed understanding will aid in the interpretation of the 
evidence suggesting TfR-mediated brain drug delivery to be either possible or impossible. Importantly, there 
is still no universal consensus as to the sorting of TfRs in BCECs, which can result in seemingly similar brain 
drug delivery studies being interpreted in opposite directions. In the next sections, we review the current 
evidence related to the uptake of iron into the brain parenchyma via TfR-mediated transport through the 
BCECs. 
Iron is an essential molecule for most living organisms since it is an essential component of or a co-
factor for a vast number of proteins, including many important enzymes (Beard et al., 1996). Iron is involved 
in basic cellular processes like oxygen transport, enzyme reactions, oxidation and reduction reactions, and in 
cell division. Iron additionally functions as a co-factor in the electron transport chain and during DNA 
synthesis (Duck and Connor, 2016). Although iron denotes an essential element in the cell, it has chemical 
properties that makes it toxic when present in excess (Anderson and Vulpe, 2009; Duck and Connor, 2016; 
Moos and Morgan, 2000). In aqueous solutions, iron exists in two forms: the reduced state (Fe2+), referred to 
as ferrous iron or its oxidative state (Fe3+), referred to as ferric iron. Iron can easily change between its ferrous 
and ferric form and this transition is the basis of many biological redox reactions, also known as Fenton 
reactions (Duck and Connor, 2016; Wardman and Candeias, 1996).  
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𝐹𝑒2+ + 𝐻2𝑂2 → 𝐹𝑒
3+ +  𝐻𝑂 + 𝑂𝐻− 
𝐹𝑒3+ + 𝐻2𝑂2 → 𝐹𝑒
2+ + 𝐻𝑂𝑂 + 𝐻+ 
 
When ferrous iron participates in the Fenton reaction by reacting with hydrogen peroxide, it results in the 
formation of a hydroxyl radical and a hydroperoxyl radical. Both are toxic free radicals and reactive oxygen 
species with the potential to damage lipids, proteins and DNA, ultimately leading to cell death, especially 
when present in excess (Anderson and Vulpe, 2009; Chevion, 1988; Duck and Connor, 2016; Stohs and 
Bagchi, 1995). Extracellularly, iron is bound to the iron-transport protein, Tf, which carry iron between cells 
in its oxidized, non-toxic form (Moos and Morgan, 2000). Intracellularly, iron remains in its reduced state, and 
if it is not required immediately for metabolic functions, it gets oxidized and incorporated by the iron storage 
protein, ferritin. This blocks ferrous iron from participating in unwanted redox reactions, thereby preventing 
the production of toxic radicals (Anderson and Vulpe, 2009; Skjørringe et al., 2015). Ferritin is comprised of 
24 polypeptide subunits and highly conserved among higher eukaryotes (Montemiglio et al., 2019). Two 
isoforms of the subunits exist, the heavy (H) and the light (L) subunit, and the composition of ferritin seems 
to be tissue specific. The H subunit is a 21 kDa protein predominantly expressed in the heart, while the L 
isoform is a 19 kDa protein predominantly expressed in the liver. By transforming ferrous iron to ferric iron, 
ferritin also exerts oxidative activity making it able to store iron in its non-toxic, ferric form (Beard et al., 1996; 
Theil, 1987). 
 
2.1. Structure and function of Tf and the TfR 
In physiological conditions, essentially all iron circulating in plasma is bound to Tf, which is a 78 kDa 
monomeric glycoprotein and a member of a closely related family of glycoproteins that also includes 
lactoferrin, melanoTf and ovoTf (Huebers and Finch, 1987; Moos and Morgan, 2000; Morgan, 1979). Tf is 
one of the most abundant plasma proteins present in concentrations ranging from 25 – 50 µM (2 – 4 µg/ml) in 
the normal human adult blood plasma (Anderson and Vulpe, 2009; Luck and Mason, 2012; H. Sun et al., 
1999). It is synthesized primarily in the liver (Moos and Morgan, 2000), but locally it is also synthesized in 
the CNS in the oligodendrocytes and choroid plexus epithelial cells (Aldred et al., 1987; Bloch et al., 1985; 
Dickson et al., 1985; Dziegielewska et al., 1984), and in the Sertoli cells of the testes (Moos and Morgan, 
2000; Skinner et al., 1984; Sylvester and Griswold, 1984). Due to the high abundance of Tf in plasma, only 
approximately 30 % of the Tf molecules are saturated with iron. Therefore, Tf functions as a buffer molecule 
if the plasma concentration of iron rapidly increases, hereby preventing the risks of accumulation of toxic non-
Tf bound iron (NTBI), which can be severely toxic in the long run as seen in hemochromatosis (Anderson and 
Vulpe, 2009; Luck and Mason, 2012). Noteworthy, the BBB does not present with excess accumulation of 
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iron in hemochromatosis, indicating that the brain stands out as the only organ that remains unaffected with 
high circulating levels of non-Tf-bound iron (Moos et al., 2000).  
The Tf molecule is composed of a single polypeptide chain with two domains of equal size, the N and 
C terminal domains. Each domain contains an iron-binding site, which has an extremely high binding affinity 
(KD = 10
-22 M) towards a single iron atom (Aisen et al., 1978; Anderson and Vulpe, 2009; Luck and Mason, 
2013); hence, each Tf molecule can carry two iron molecules in their ferric form. Since Tf has two binding 
sites for iron, different forms of Tf exist. Non-iron bound Tf is referred to as apo-Tf, the binding of one iron 
atom is referred to as mono-ferric Tf, while the binding of two irons is referred to as di-ferric Tf, or simply 
holo-Tf  (Luck and Mason, 2013; 2012; Moos and Morgan, 2000; Tortorella and Karagiannis, 2014). The 
binding of iron to Tf is pH-dependent. At a physiological pH of 7.4, the binding affinity of Tf to iron is highest, 
making the binding almost irreversible, but at pH levels lower than 6.5, the binding affinity of Tf to iron is 
lowered, causing a release of iron (Moos and Morgan, 2000; Morgan, 1983). The primary role of Tf in plasma 
and interstitial fluids of the body is to function as an iron carrier that accepts iron released from cells and 
transport it to other cells (Moos and Morgan, 2000; Moos et al., 2007). Due to the hydrophilic nature of the Tf 
molecule and its high affinity towards the TfR, Tf-bound iron is mainly taken up by cells expressing the TfR 
(Luck and Mason, 2012; Moos et al., 2007). The Tf molecule undergoes a conformational change when bound 
to iron, which is important in relation to its selective recognition by the TfR (H. Sun et al., 1999).  
Two different TfRs have been recognized. These are referred to as TfR1 and TfR2, of which the TfR1 
has been most extensively studied. They show homologies around 45 – 66 % in the extracellular domain but 
present with different expression patterns in the body. The TfR2 is mainly expressed in tissues involved in 
regulating iron metabolism, such as the liver and small intestines, while the TfR1 is generally found on the 
surface of most body cells (Tortorella and Karagiannis, 2014; Trinder and Baker, 2003). Active proliferating 
cells or cells that have specialized iron requirements, like immature erythroid cells with a large requirement of 
iron for haemoglobin synthesis, express higher levels of TfR1 (Gatter et al., 1983; Tortorella and Karagiannis, 
2014). TfR2 has a 25-fold lower affinity towards Tf compared to TfR1 (Kawabata et al., 2000; Tortorella and 
Karagiannis, 2014).  
The human TfR1 is a transmembrane glycoprotein consisting of two identical subunits of 90 kDa 
linked by disulphide bonds (the term ‘TfR’ will be used throughout the remainder of this chapter referring to 
‘TfR1’). Each subunit is a type II membrane protein made up of a short N-terminal cytoplasmic tail, containing 
a consensus internalization motif, a hydrophobic transmembrane domain, and a large globular extracellular C-
terminal domain. The extracellular domain contains the binding site for Tf. Each subunit can bind one Tf 
molecule, thereby having the capacity of internalizing four ferric irons during each cycle of TfR-mediated 
endocytosis (Aisen et al., 1978; Anderson and Vulpe, 2009; Y. Cheng et al., 2004). At physiological pH around 
7.4, the TfR binds holo-Tf with the highest affinity (KD ~ 4 nM). Mono-ferric Tf binds with a lower affinity to 
the TfR (KD ~ 32 – 36 nM, depending on which domain of the Tf molecule iron is bound to) than holo-Tf. 
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Apo-Tf has a very low affinity for the TfR and most likely does not bind at neutral pH (Eckenroth et al., 2011; 
Luck and Mason, 2012; Mason et al., 2009). However, as the pH decreases the affinity for apo-Tf increases 
(Luck and Mason, 2013). Approximately 15 – 20 % of the TfRs are residing on the cell surface (Johnsen and 
Moos, 2016; Luck and Mason, 2013; van Gelder et al., 1995; Visser et al., 2004b). Upon binding of holo-Tf, 
the Tf-TfR complex is endocytosed through clathrin-coated pits (Mayle et al., 2012; Tortorella and 
Karagiannis, 2014; Yashunsky et al., 2009). 
 
2.2. Mechanism of TfR endocytosis and iron uptake into the brain 
Iron must be transported across the BBB to enter the CNS (Skjørringe et al., 2015). The iron uptake is a highly 
regulated process since the presence of iron in insufficient amounts or in excess within the CNS is associated 
with neurological diseases (Altamura and Muckenthaler, 2009; Duck and Connor, 2016). The mechanisms of 
uptake and transport of iron across the BCECs constituting the BBB have been a matter of debate for long 
(Figure 3)(Benkovic and Connor, 1993; Burdo et al., 1999; 2001; Duck and Connor, 2016; Friden et al., 1991; 
Lee et al., 2000; Leitner and Connor, 2012; Moos et al., 2007; Moos and Morgan, 2001; Moos et al., 2006; 
Pardridge et al., 1991; Skjørringe et al., 2015). The endothelial cells of the vasculature do not express TfR 
despite their immediate access to circulating holo-Tf, except for the endothelial cells of the brain 
microvasculature forming the BBB (Jefferies et al., 1984). The TfR has therefore been widely explored as a 
target for specific delivery of drugs to the brain by attempting to use Tf or antibodies specifically targeting this 
receptor (Duck and Connor, 2016; Friden et al., 1991; Gosk et al., 2004; Johnsen and Moos, 2016; Lee et al., 
2000; Moos and Morgan, 2001). This suggested a TfR-mediated transcytosis pathway instead of the 
endocytosis pathway observed in other cells. The first observation of TfR-mediated transcytosis was published 
in 1987 by Fishman and colleagues (Fishman et al., 1987). They studied the distribution of 125I-labelled Tf in 
the brain and its microvasculature, and demonstrated that even though most labelled Tf remained within the 
vasculature, intact Tf was also present in the brain parenchyma, indicating transcytosis of Tf across the brain 
endothelium (Fishman et al., 1987).  
In studies using a radiolabeled antibody (clone OX26), which specifically targets the rat TfR without 
interfering with the binding site for Tf, passage across the BBB was also observed (Friden et al., 1991; Lee et 
al., 2000; Pardridge et al., 1991). Additionally, it was shown that when the antibodies were coupled to a 
therapeutic protein, increased amounts of this therapeutic protein entered the brain parenchyma in comparison 
to one not coupled to an antibody. These studies also observed a large retention of the complexes within the 
brain vasculature (Duck and Connor, 2016; Pardridge et al., 1991; Y. Zhang and Pardridge, 2001a), which was 
also the main observation in subsequent studies by Moos and Morgan, when they explored the transcytosis 
mechanisms of the TfR (Gosk et al., 2004; Moos and Morgan, 2001). Based on the capillary depletion 
technique and immunohistochemical mapping, they observed large retention of the OX26 antibody within the 
BCECs with only a small fraction present in the neurons situated periventricularly. It was concluded that the 
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amount of OX26 accumulation in the brain parenchyma was too small to justify the conclusion that the TfR 
undergoes transcytosis to deliver the OX26 antibody across the BBB (Moos and Morgan, 2001). They 
additionally based these conclusions on previous observations on much higher amounts of iron entering the 
brain compared to Tf (Moos and Morgan, 2000; C. M. Morris et al., 1992; Taylor et al., 1991; Ueda et al., 
1993), indicating a lack of transcytosis of Tf by the TfR. This points towards the normal pathway in other 
types of cells where only iron is exported from the endocytosed vesicles, while the Tf is recycled with the TfR 
to the cell membrane (Moos and Morgan, 2001). In addition, the presence or lack of the divalent metal 
transporter 1 (DMT1) in the brain endothelial cells have been a matter of debate in regards to understanding 
the mechanisms of the TfR at the BBB (Burdo et al., 2001; Moos et al., 2006; Skjørringe et al., 2015). Inside 
the CNS, DMT1 expression has been confirmed in neurons, oligodendrocytes, astrocytes and in the ependymal 
epithelium, while studies on its expression within the brain endothelium have resulted in conflicting 
observations (Duck and Connor, 2016). One group was not able to confirm the expression of DMT1 in the 
microvessels but found expression in the neurons, despite the use of three different anti-DMT1 antibodies 
targeting different epitopes of DMT1 (Moos et al., 2006; Moos and Morgan, 2004). Additionally, gene 
expression analysis failed to confirm the presence of DMT1 in brain endothelial cells from both rat and mice 
brains (Enerson and Drewes, 2006; Gunshin et al., 1997; Skjørringe et al., 2015). Recently, however, the 
expression of DMT1 was confirmed in isolated brain capillaries, in primary isolated BCECs cultured under in 
vivo-like conditions, and in immortalized endothelial cells (Burkhart et al., 2016; Chiou et al., 2018a; Klomp 
et al., 1996; McCarthy and Kosman, 2013; 2012). 
Two different pathways of TfR-mediated iron delivery to the brain have therefore been proposed 
(Figure 3) (Khan et al., 2018). The first involves the previously described pathway of TfR-mediated 
endocytosis, where holo-Tf binds to the TfR and becomes internalized into endosomes (Roberts et al., 1993). 
Inside the endosomes, iron detaches from Tf due to the lowering of the pH, leaving only apo-Tf bound to the 
TfR. The released iron is reduced to ferrous iron and translocated to the cytoplasm by DMT1. The apo-Tf 
together with the TfR recycle to the apical membrane or become stored inside the BCEC (Chiou et al., 2018a). 
Iron residing in the cytoplasm can be used by the BCECs, stored in ferritin, or exported by ferroportin residing 
at the basolateral membrane in collaboration with ferroxidases that oxidize iron back to its ferric state. Inside 
the brain parenchyma, iron is bound to Tf, or taken up by the cells of the CNS (Duck and Connor, 2016; Moos 
et al., 2007; Skjørringe et al., 2015). Tf is secreted locally in the CNS by oligodendrocytes and the choroid 
plexus epithelial cells (Aldred et al., 1987; Bloch et al., 1985; Dickson et al., 1985; Dziegielewska et al., 1984; 
Moos and Morgan, 2000) with indications of Tf production in BCECs as well (Chiou et al., 2018a; Connor et 
al., 2011; Duck et al., 2017). The expression of the iron-related proteins at the neurovascular unit was recently 
examined showing that the ferric reductases expressed by the BCECs in vivo and in vitro were Steap 2 and 3 
(Burkhart et al., 2016). Expression of the major ferrireductase in the duodenum, Dcytb, was also reported for 
immortalized human brain microvascular endothelial cell line, indicating that Dcytb might provide 
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ferrireductases activity at the BBB (McCarthy and Kosman, 2012). Additionally, BCECs, astrocytes and 
pericytes all provide the activity necessary for oxidation of ferric iron to facilitate the release of iron from 
ferroportin. The identified ferroxidases were ceruloplasmin (both the soluble and the GPI-anchored form), and 
hephaestin. The expression of the ferroxidase proteins was highest in the astrocytes and pericytes indicating 
that these cells might be the main sources of ferroxidase activity (Burkhart et al., 2016; Klomp et al., 1996; 
McCarthy and Kosman, 2013; B. N. Patel and David, 1997). 
The other theory involves transcytosis of the Tf-TfR complex across the BCECs without the 
involvement of DMT1. Again, holo-Tf binds to the TfR, which triggers its internalization into endosomes. 
These endosomes traverse the cell and docks at the abluminal membrane, where either iron or holo-Tf is 
proposed to be released into the brain parenchyma (Moos et al., 2007; Skjørringe et al., 2015). This theory, 
however, is also a matter of debate due to several flaws (Simpson et al., 2015). The amount of iron transported 
in to the brain is much higher than that of Tf (Moos and Morgan, 2000; C. M. Morris et al., 1992; Taylor et 
al., 1991; Ueda et al., 1993), suggesting that only iron is transported into the brain parenchyma, while Tf 
recycles to the plasma. Instead of Tf transport from blood to the brain, Tf is synthesized locally within the 
CNS by the choroid plexus cells and oligodendrocytes (Aldred et al., 1987; Bloch et al., 1985; Dickson et al., 
1985; Dziegielewska et al., 1984). Therefore, Tf probably remains bound to the TfR if iron is released. Iron 
detaches from the Tf-TfR complex either inside the acidic endosomes due to loss of affinity to Tf at low pH, 
or when the Tf-TfR complex docks at the abluminal surface. Since the neutral pH of the brain interstitium does 
not favor the release of iron from holo-Tf, theories on how iron is released at the abluminal membrane, includes 
the secretion of factors like citrate or ATP from the astrocytes (Duck and Connor, 2016; Moos et al., 2007). 
The transcytosis theory also has difficulties in explaining, how the BCECs acquire iron for their own need 
(Simpson et al., 2015). The expression level of the iron-storage protein ferritin is high in the BBB, suggesting 
that the BBB can act as an iron reservoir, especially in the developing brain (Duck and Connor, 2016; Moos, 
1995; Simpson et al., 2015). Additionally, studies using rats with mutations of DMT1 reveals a much lower 
level of iron within the brain and high levels of holo-Tf in plasma (Burdo et al., 1999; Simpson et al., 2015), 
pointing to an important role for DMT1 in the transport of iron across the BBB. In addition to the fact that 
BCECs are able to accumulate iron on their own, this suggests that the transport of iron across the BBB is not 
through transcytosis of Tf (Duck and Connor, 2016; Simpson et al., 2015; Skjørringe et al., 2015). These 
findings have recently been corroborated in studies performed in stem cell-based in vitro models of human 
BBB (Chiou et al., 2018a; Chiou and Connor, 2018; Chiou et al., 2018b), where the importance of DMT1 in 
the iron transport into the brain was underscored. Interestingly, the authors found that the main fraction of iron 
transported to the brain was protein-bound and sensitive to DMT1 inhibition, hereby suggesting a model where 
the iron atoms dissociate from the Tf protein, after which it can be pumped out of the BCEC by ferroportin or 
associate with the intracellular Tf pool to become secreted to the brain as protein-bound iron (Figure 3) (Chiou 
et al., 2018a). Free iron released to the brain parenchyma can associate with parenchymal Tf protein, possibly 
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synthesized by the BCECs themselves (Connor et al., 2011; Duck et al., 2017). Furthermore, an interesting 
function of ferritin in mediating transport of iron to the brain was also described, highlighting the complexity 
of the iron transport model at the BBB (Chiou, Neal, Bowman, Lippmann, Simpson, and Connor, 2018a; 
Montemiglio et al., 2019). Such function of ferritin was recently exploited for drug delivery purposes too 
(Chen et al., 2017; Fan et al., 2018; Zhai et al., 2018). Thus, these recent findings support the notion that the 
BCECs do not simply represent conduits for iron transport to the brain, but rather participate actively by 
regulating both the uptake and transendothelial transport of free or protein-bound iron (Chiou et al., 2018a; 
Duck and Connor, 2016; Simpson et al., 2015). 
 
3. The TfR as a target for brain drug delivery 
In recent years, a large focus has been on the development of biological therapeutics for treating CNS-related 
disorders. For example, several pharmaceutical and biotechnology companies have pursued antibody variants 
targeted to the ß-amyloid plaques associated with Alzheimer’s disease (e.g. solanezumab (Doody et al., 2014), 
bapineuzumab (Salloway et al., 2014a), crenezumab (Cummings et al., 2018), gantenerumab (Ostrowitzki et 
al., 2017), and aducanumab (Sevigny et al., 2016)), or α-synuclein associated with Parkinson’s disease (e.g. 
prasinezumab (Jankovic et al., 2018)(NCT03100149) and BIIB054 (NCT03318523)), and the therapeutic 
efficacy of each antibody was shown continuously in preclinical models (Sevigny et al., 2016). However, while 
several of the antibodies for the treatment of Alzheimer’s disease were successfully progressed into clinical 
trials, all of the prominent projects either failed or were halted in phase 3, largely due to futility (Biogen, 2019; 
Doody et al., 2014; “Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial | Eli Lilly and 
Company,” 2016; Roche, 2019; Salloway et al., 2014b). Specialized trials in different subpopulations of 
Alzheimer’s disease have also provided negative findings (Honig et al., 2018; Liu-Seifert et al., 2015; Siemers 
et al., 2016), and a highly anticipated project regarding an antibody derived from drug discovery in very old 
people without dementia also recently failed (Biogen, 2019; Servick, 2019). Eisai’s BAN2401 is currently 
being tested in a phase 3 trial in patients with mild Alzheimer’s disease and cognitive impairment (Logovinsky 
et al., 2016; Satlin et al., 2016; Tucker et al., 2015). A common denominator of all of these failed clinical trials 
was that brain accumulation of the therapeutic antibody depended on a passive mechanism of uptake across 
the BBB. The resulting level of transport is therefore expected to be low, which may have decreased the 
therapeutic efficacy of an otherwise very potent drug. There are several ways of increasing the drug exposure 
in the brain, but for biological (large molecule) therapeutics transport via receptor or transporter proteins on 
the surface of BCECs is preferable (Preston et al., 2014). As mentioned previously, the TfR is the most widely 
used target for this purpose, and may have the potential of increasing the efficacy of the already existing 
antibody-based drugs against neurodegenerative diseases, e.g. via bi-specific antibody designs (see below). 
 The relevance of using the TfR as a target for drug delivery has remained largely unquestioned for 
several decades. The original interest in this receptor system was based on the observation that endothelial 
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cells of the brain expressed TfRs as opposed to endothelial cells in other organs (Jefferies et al., 1984). While 
this does not mean that the TfR is a receptor molecule only of the brain, these observations suggested that the 
selective expression in the brain capillaries could lead to preferential accumulation of TfR-targeted substances 
in the brain to a larger degree than for those more ubiquitously expressed in the systemic vasculature (Friden 
et al., 1991; Jefferies et al., 1984). In the years following this observation, the TfR gained more and more 
attention because seminal papers by Friden and colleagues showed that molecules (e.g. antibodies) directed 
against this receptor could efficiently accumulate along the brain capillaries, and, more importantly, could be 
transported across the endothelial layer of the BBB and enter the brain parenchyma (Friden et al., 1991; 1992; 
1993). This sparked the hope that this receptor system could be a passageway to circumvent the low 
permeability of the BBB and stimulated the idea that drugs could be attached to TfR-binding molecules and 
be delivered into the brain in a ‘Trojan horse’-like fashion (Boado and Pardridge, 2011). In the almost 30 years 
that have passed since these initial findings, the research field interested in the TfR as a brain drug delivery 
target has grown dramatically with new studies being published on the subject with high frequency. Therefore, 
the amount of accumulated data is large with most of it suggesting the system to work efficiently (Johnsen and 
Moos, 2016; Pardridge, 2014). Many studies report therapeutic outcomes, whereas others systematically 
quantify the amount of substance transported into the brain (van Rooy et al., 2011a; 2011b; Y. Zhang et al., 
2003b; Y. Zhang and Pardridge, 2001a). While these absolute amounts of drug transported to the brain 
parenchyma most often fall way below 1 % of the injected dose per gram (%ID/g), it seems to be sufficient 
for treatment success in preclinical models of disease (Johnsen and Moos, 2016). However, despite these large 
amounts of encouraging results, there has only been very little translation of these findings into a clinical 
setting (Okuyama et al., 2019), and thus, there is a clear need for more data shedding light not only on the 
therapeutic outcomes in preclinical models of disease but also on the mechanistic aspects of the transport 
process, which may provide valuable insight as to why many current strategies have failed so far. In addition, 
potential publication bias may also result in negative findings never being published, hereby making important 
information unavailable for the broader research community. Thus, several aspects pertaining to the use of the 
TfR as a target for brain drug delivery need to be clarified before clinical use can become a realistic ambition.  
In the next sections, we review the use of TfR as a target for drug delivery in the context of antibody-
based medicines and nanocarriers. The underlying literature foundation was derived from several PubMed 
search strings using the search criteria “transferrin receptor AND brain AND drug delivery” or “transferrin 
receptor AND (brain OR “central nervous system”)” (last search was performed on July 10th, 2019). The 
PubMed search yielded a total of 286 and 1178 papers, respectively, of which 216 papers were sorted with 
respect to type of drug delivery system (i.e. antibodies or nanocarriers) and used for the individual sections 
below. The following sections will first describe the different ligands and monoclonal antibodies used to target 
the TfR at the BBB and investigate how the functionality of these different ligands depict treatment outcome 
when they carry therapeutically active molecules as their cargo. Additionally, the different kinds of 
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nanocarriers that have been functionalized with TfR-targeting ligands are described (e.g. liposomes and 
polymer nanoparticles). Lastly, we come with suggestions on how to modify the different drug delivery 
strategies to improve the subsequent transport into the brain. These include modifications of affinity and 
avidity in antibody-based medicines, as well as the addition of cell-penetrating peptides or stimuli-sensitive 
drug release in nanocarrier systems. 
  
3.1. Ligands 
The choice of ligand in TfR-targeted drug delivery system varies greatly across studies. It encompasses both 
the endogenous ligand, Tf, together with several different antibodies and peptides that bind to different 
epitopes of the receptor molecule. The endogenous Tf molecule has been used extensively throughout many 
studies in the past 30 years. It has the advantage that it can bind to the ‘normal’ binding pocket on the TfR 
molecule and initiate the normophysiological mechanism of endocytosis of the Tf-TfR complex into the 
BCEC. This endocytosis process will likely be affected by the size of the drug or nanocarriers attached to the 
Tf molecule, where endothelial uptake of larger structures may distort the normal intracellular sorting 
mechanism (Freskgård and Urich, 2017; Fullstone et al., 2016). As described earlier, the main body of data on 
the dynamics of the TfR in the BCECs suggests that neither the receptor nor the Tf molecule transcytoses into 
the brain parenchyma from the luminal side of the vessel (Duck and Connor, 2016; Simpson et al., 2015; 
Skjørringe et al., 2015). Instead, the iron is released from its binding to Tf, after which it is pumped out of the 
endosome and subsequently out of the BCEC (Skjørringe et al., 2015). Since the Tf molecule has allowed for 
drug accumulation in the brain parenchyma using a wide variety of constructs and nanocarriers, there must 
therefore be a mechanism, which can release the drug or nanocarrier from the TfR and transport it inwards to 
the brain parenchyma (Boado and Pardridge, 2011; Johnsen and Moos, 2016; Wiley et al., 2013). This 
mechanism has yet to be described (Johnsen et al., 2017).  
 Another widely used TfR-targeting molecule is the OX26 antibody, which recognizes the rat TfR. 
OX26 was originally described by Jefferies and colleagues to specifically bind the rat TfR with high affinity 
without interfering with the normal binding site of endogenous Tf (Hill et al., 1985; Jefferies et al., 1984; 
1985). It was also found to label the TfR in various tissues, but not along the blood vessels in them, and it was 
used to underscore the observation that TfRs could only be detected in capillaries of the brain (Friden et al., 
1991; Jefferies et al., 1984). Within a few years, OX26 was tested for its ability to be transported across the 
BBB, and the positive findings of these investigations sparked a long-lasting claim that due to the successful 
transport of the OX26 antibody, the TfR must also have been transcytosed (Bickel et al., 1993; Friden et al., 
1993; 1991). Like for the endogenous Tf molecule, OX26 has now been tested as a targeting molecule, both 
as fusion constructs with different drugs and together with different kinds of nanocarriers, leading to 
therapeutic efficacy of several preclinical models of brain disease, including Parkinson’s disease (Pardridge, 
2005; Y. Zhang et al., 2003b; 2004a), Alzheimer’s disease (Y. Saito et al., 1995), stroke (Song et al., 2002; Y. 
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Zhang and Pardridge, 2006; 2001a; 2001b), and especially the brain cancer type, glioblastoma multiforme 
(GBM) (Xia et al., 2007; Y. Zhang et al., 2003a; 2004b; 2002), which will be elaborated in the next sections. 
Murine analogous variants of OX26 (i.e. antibodies with high affinity against the murine TfR) have also been 
produced (e.g. clones 8D3 and RI7217), and the existing data suggests both transcytosis or inability to do so 
(Bourassa et al., 2019; Jeong Lee and Pardridge, 2000; Lee et al., 2000; 2002; Manich et al., 2013; Paris-
Robidas et al., 2016; 2011; Y. Zhang and Pardridge, 2005). It should be noted that determining transcytosis is 
still a big methodological challenge, since techniques like brain capillary depletion could overestimate the true 
level of transport (Freskgård et al., 2014; Watts and Dennis, 2013). However, there has been good progress in 
validating transport of TfR-targeted brain medicines, especially when binding to intraparenchymal targets can 
be specifically determined (Sehlin et al., 2016).  
 In addition to using endogenous Tf or antibodies, some groups have developed small peptides that 
bind to the TfR (Kuang et al., 2016; Z. Wang et al., 2015). The advantages of such small peptides are that the 
resulting construct does not compete with the endogenous Tf for binding to the receptor, and that potential 
side effects imposed by the presence of the Fc effector domain of the antibody are avoided (Couch et al., 2013). 
However, peptides are known to be very unstable in plasma and bind their target with very low affinity, which 
may make them less relevant compared to antibodies. Also, in comparison with the two abovementioned 
strategies of TfR-targeting, there is less data on the use of peptides for this purpose, although the popularity is 
increasing (Bi et al., 2016; L. Cui et al., 2018; Kuang et al., 2013; Liang et al., 2018; Prades et al., 2012; Z. 
Wang et al., 2015; Zong et al., 2014). For example, a recent study compared the functionality of different 
peptides targeting the TfR and low-density lipoprotein receptor-related protein 1 (LRP1) on polymer 
nanoconjugates showing that the choice of peptide to target the TfR is important for the subsequent uptake 
potential in the brain (Israel et al., 2019). Even less information is available regarding the use of aptamers as 
ligands for TfR-targeted brain drug delivery (Macdonald et al., 2017; 2016; McConnell et al., 2018; C. Mu et 
al., 2013). 
 
3.2. Drug conjugates targeting the TfR 
The use of the TfR as a target for brain drug delivery using conjugates of a drug and a targeting molecule was 
initiated by Friden and colleagues in the early 1990s (Friden et al., 1991). Using methotrexate as a model 
drug, they could show that attachment to the OX26 antibody increased the brain parenchymal levels of this 
molecule substantially compared to free drug, although the absolute quantity of methotrexate in the brain after 
employment of this targeting strategy was still below 0.3 %ID (Friden et al., 1991). These studies indicated 
that small molecule drugs could be transported into the brain using a TfR-targeting strategy but did not address 
the possibility of transporting larger molecules like proteins across the BBB. This was proven shortly after in 
a study showing efficient brain delivery of nerve growth factor (NGF) conjugated to an anti-TfR antibody 
(Friden et al., 1993). The transport of NGF across the BBB was shown to increase the survival of both 
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cholinergic and non-cholinergic neurons, which is of high relevance in treatments for Alzheimer’s disease 
(Bäckman et al., 1995; 1996; Friden et al., 1993; Granholm et al., 1994). The construct also improved the 
therapeutic outcome in a model of Huntington’s disease and after NMDA-induced brain lesions (Charles et 
al., 1996; Kordower et al., 1994), and spinal cord motor neuron function after delivery of glial-derived 
neurotrophic factor (GDNF) instead of NGF (Albeck et al., 1997). Attempts were also made to develop anti-
TfR antibodies for use in primates and humans (Friden et al., 1996; Walus et al., 1996), and constructs were 
designed with endogenous Tf as a targeting ligand (Hagihara et al., 2000; Laske et al., 1997; X. B. Li et al., 
2000; Martell et al., 1993; Weaver and Laske, 2003). While most of the transport of OX26 across the BBB 
was ascribed to receptor-mediated transcytosis with the TfR like what was observed for Tf, some claimed that 
the co-localization of OX26 with the Golgi apparatus suggested the transport pathway to be adsorptive-
mediated transcytosis (Broadwell et al., 1996). In parallel with these findings and in the following years, 
Pardridge and colleagues published a series of studies where they investigated the possibility of using the TfR 
as a target for BBB transport, especially using the OX26 antibody (Bickel et al., 1993; Y. S. Kang et al., 1994; 
Y. S. Kang and Pardridge, 1994; Lee et al., 2002; 2000; Pardridge et al., 1995; 1994; 1998; Shin et al., 1995; 
Song et al., 2002; Wu et al., 1996; Wu and Pardridge, 1999; 1998; 1996; Wu et al., 2002; Y. Zhang and 
Pardridge, 2001a). Like Friden, Pardridge showed improved brain uptake of OX26, and provided evidence 
on how to conjugate this antibody to different molecules including brain-derived neurotrophic factor (BDNF) 
(Pardridge et al., 1998; 1994; Y. Zhang and Pardridge, 2006; 2001b), epidermal growth factor (EGF) (Deguchi 
et al., 1999), fibroblast growth factor (FGF) (Song et al., 2002), vasoactive intestinal peptide (VIP) (Bickel et 
al., 1993), antisense oligonucleotides (Y. S. Kang et al., 1995; Wu et al., 1996; Xia et al., 2007), peptide nucleic 
acids (PNAs) (Pardridge et al., 1995), and different therapeutic peptides (Bickel et al., 1995; Y. Saito et al., 
1995). Furthermore, the pharmacokinetic profile of the different constructs was described (Wu et al., 2002; 
Wu and Pardridge, 1998), as well as the importance of choosing either carboxy or amino terminal coupling to 
the therapeutic protein (Pardridge et al., 1998). Most prominently, these constructs could provide 
neuroprotection in cerebral ischemia and stroke models in the rat (Song et al., 2002; Wu and Pardridge, 1999; 
Y. Zhang and Pardridge, 2006; 2001b; 2001a), and the findings of efficient transport into the brain could 
largely be recapitulated in the mouse using either the 8D3 or RI7217 antibodies (Boado et al., 2009; Jeong Lee 
and Pardridge, 2000; Lee et al., 2000; Y. Zhang and Pardridge, 2005). Transendothelial transport was also 
shown by others for 8D3 reconfigured to be a -amyloid PET tracer (Hultqvist et al., 2017; Sehlin et al., 2016; 
Syvänen et al., 2017). Later, the Pardridge group developed single chain variable fragments (scFv) and 
chimeric anti-TfR antibodies, which could be fused to numerous different therapeutic proteins (Boado et al., 
2009; 2000; J. Y. Li et al., 1999). For example, a genetically engineered chimeric anti-TfR antibody could 
deliver erythropoietin (EPO) (Chang et al., 2018), N-sulfoglucosamine sulfohydrolase (SGSH) (Boado et al., 
2018), tumor necrosis factor receptor (TNFR) (Chang et al., 2017; Sumbria et al., 2013a; 2013b; Zhou et al., 
2011a; 2011d), GDNF (Fu et al., 2010; Sumbria et al., 2013a; Zhou et al., 2011b; 2010), iduronate-2-sulfatase 
Jo
ur
na
l P
re
-p
ro
of
 18 
(IDS) (Zhou et al., 2012), -L-iduronidase (IDUA) (Boado et al., 2011), anti-survivin siRNA (F. Wang et al., 
2011), and anti--amyloid scFvs (Boado et al., 2010; Zhou et al., 2011c). Of note, the brain uptake of these 
different constructs based on a chimeric antibody (Boado et al., 2010; Zhou et al., 2012; 2011c; 2011a; 2010) 
differed substantially compared to constructs based on OX26 (Y. S. Kang et al., 2000; Pardridge et al., 1998; 
Y. Saito et al., 1995) (2.2 – 3.5 %ID/g versus 0.12 – 0.15 %ID/g, respectively), showing that despite all 
antibodies having high affinity towards the TfR, the resulting transport cannot be expected to be similar (KD 
ranging between 96 pM – 5 nM (Boado et al., 2011; 2010; 2009; Thom et al., 2018; Zhou et al., 2012; 2011d; 
2011a; 2010)). In addition to the choice of therapeutic entity, redox-sensitive linkers were also incorporated to 
enable activation or release of the therapeutic entity from the targeting ligand (Bickel et al., 1995; Y. S. Kang 
et al., 2000). Furthermore, results from a recent phase 1/2 trial showed that high affinity targeting of anti-TfR 
antibodies fused to IDS could reduce CSF levels of heparan sulfate in patients suffering from 
mucopolysaccharidosis II (MPSII), illustrating that TfR-targeted brain drug delivery is a reasonable strategy 
for treatment of brain-related disorders (Okuyama et al., 2019; Sonoda et al., 2018; Tanaka et al., 2018). 
Despite the vast amounts of evidence presented for the strategy of targeting the TfR with high affinity 
antibodies, the essence of these findings have been questioned by numerous groups (Manich et al., 2013; Moos 
and Morgan, 2001; Niewoehner et al., 2014; Paris-Robidas et al., 2011; Yu et al., 2011). The effective transport 
of OX26 antibodies across the BBB was first questioned by Moos and Morgan (2001), who showed that it 
remained confined in the BCECs of the capillary wall with little evidence of transport into the brain 
parenchyma (Moos and Morgan, 2001). This highlighted the possibility that the OX26 antibody (and other 
analogous high affinity antibodies against different species) would be so tightly bound to the TfR that release 
during the endosomal sorting process was unlikely (Dennis and Watts, 2012; Freskgård and Urich, 2017). 
Similar observations were also obtained in the mouse, again suggesting that the antibody could not be detected 
in post-vascular compartments of the brain after intravenous administration (Alata et al., 2014; Cabezón et al., 
2017; 2015; Manich et al., 2013; Paris-Robidas et al., 2016; 2011; Webster et al., 2017). While these findings 
were discouraging for the field of TfR-targeted brain drug delivery, they did point towards the option that the 
distorted transport of antibodies into the brain could be recovered by modulating the binding mode between 
the antibody and the TfR (Lichota et al., 2010). A decade later, the work by Yu et al. showed that the binding 
mode could indeed be modified by decreasing the affinity of the antibody towards the TfR (Yu et al., 2011). 
This led to a higher accumulation of antibodies in the brain parenchyma (0.2 – 0.6 %ID/g), and could also 
significantly reduce the expression of the Alzheimer’s disease-related enzyme, beta-secretase 1 (BACE1), with 
a bi-specific antibody targeting both the TfR and the BACE1 enzyme (Yu et al., 2011). These results were 
corroborated in subsequent studies showing that the reason for the low affinity antibodies accumulating in the 
brain was because they could circumvent intracellular sorting targeted for degradation in the lysosomes, a 
location shown to be the main accumulation site for the high affinity antibodies (Bien-Ly et al., 2014) and 
liposomes functionalized with high affinity antibodies (Johnsen et al., 2017). Although difficult to directly 
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prove experimentally, this data suggested that the TfR-targeting molecule needs to be able to dissociate from 
the receptor during the endosomal sorting process, because too long occupancy on the receptor is a signal for 
the cell to target the strongly binding molecules towards degradation in the lysosomes (Freskgård and Urich, 
2017; Watts and Dennis, 2013). Related to this, strong indirect evidence has been provided to suggest that 
antibody constructs with proper design can be released from the TfR, enter the brain, and bind to an 
intraparenchymal target, hereby underscoring that the antibody binding mode interferes with the transport 
process (Hultqvist et al., 2017; Niewoehner et al., 2014; Sehlin et al., 2016; Yu et al., 2011). In addition to 
affinity, others have suggested that the binding mode also could be changed either by modulating the avidity 
(Hultqvist et al., 2017; Niewoehner et al., 2014; Yu et al., 2014), engineering dual variable domain antibodies 
(Karaoglu Hanzatian et al., 2018), or introduce pH-sensitivity in the variable domain of the TfR-targeting 
antibody (all explained in detail later)(Sade et al., 2014). In addition to using antibodies for transporting drugs 
across the BBB, different conjugates have been made of endogenous Tf and molecules such as horseradish 
peroxidase (HRP, as a model drug) or nucleic acids for therapeutic gene expression in the brain parenchyma 
(Osborn et al., 2008; Roberts et al., 1993; Visser et al., 2004a). The observed efficiency of Tf in transporting 
drugs has also been utilized by conjugating the protein with diphtheria toxin for cytotoxic effects in brain 
cancer (Weaver and Laske, 2003). This construct was taken into clinical trials, although it was halted at phase 
3 (NCT00083447). Interestingly, only a few studies have investigated constructs of drug-conjugated TfR-
targeted peptides; however, it was shown that the T7 peptide could increase the brain accumulation of shRNA 
to mediate vascular endothelial growth factor (VEGF) knockdown for GBM treatment (Kuang et al., 2016). 
 
3.3. Liposomes 
With increasing amounts of data suggesting the TfR to be a relevant target for brain drug delivery published 
through the first part of the 1990s, some researchers started to investigate the possibility of attaching larger 
nanocarriers to the different TfR-targeting molecules to increase the brain concentration of the cargo 
encapsulated in the nanocarriers. Like for the TfR-targeted drug constructs mentioned above, this field was 
also pioneered by the studies of Pardridge and colleagues, who in the mid 1990s showed that this concept 
could indeed be feasible (Huwyler et al., 2002; 1996; Shi et al., 2001a; Shi and Pardridge, 2000; Shi et al., 
2001b; Y. Zhang et al., 2004b; 2004a; Y.-F. Zhang et al., 2003). Using the OX26 antibody as the targeting 
molecule, liposomes containing daunomycin were administrated to rats, and the daunomycin cargo could after 
a period of circulation clearly be found associated with the brain (Huwyler et al., 1996). The first studies did, 
however, not provide any evidence of effective BBB passage, but instead showed that the brain association of 
daunomycin increased with tuning of the antibody density on the liposomes surface (Huwyler et al., 1996). 
Interestingly though, the fraction of drug that reached the brain was an order of magnitude lower than what 
was previously reported for the OX26 drug constructs alone (Johnsen and Moos, 2016). This suggested that 
the transport of larger nanocarriers is much less efficient than antibodies alone, although it may be 
Jo
ur
na
l P
re
-p
ro
of
 20 
compensated by the fact that nanocarriers can carry a large drug load (Huwyler et al., 1996). Conversely, 
liposome delivery with an efficiency comparable to OX26 alone has also been reported (Y.-S. Kang et al., 
2016). These preliminary findings were later expanded upon in subsequent studies using the same OX26-
functionalized liposomes administrated to monolayers of the immortal rat BCEC line, RBE4 (Cerletti et al., 
2000; Huwyler et al., 2002). In these experiments, the liposomes were found to transcytose, as was also 
expected to happen in vivo, and they could also protect P-gp substrates from efflux during endocytosis into 
the BCECs (Cerletti et al., 2000; Huwyler et al., 2002). Later, different liposomal formulations were tested for 
encapsulation of nucleic acids, i.e. by including positively charged phospholipids, which allowed for having 
both plasmid DNA or small RNAs as the drug cargo (Shi et al., 2001b; 2001a; Shi and Pardridge, 2000; Y. 
Zhang et al., 2004b; 2004a; Y.-F. Zhang et al., 2003). With this drug delivery strategy, it was possible to induce 
expression of ß-galactosidase in the brain after administrating the liposomes intravenously, and the treatment 
could be specified to the brain by having the plasmid DNA product expressed under the control of a glial 
fibrillary acidic protein (GFAP) promotor instead of the more classical SV promotor (Y. Zhang et al., 2004a; 
2003b; Zhao et al., 2010; Zhu et al., 2004). The concept also showed benefit in preclinical brain disease models, 
e.g. with an increase of tyrosine hydroxylase expression (due to delivery of plasmid DNA) in dopaminergic 
neurons in a model of Parkinson’s disease (Y. Zhang et al., 2004a; Y.-F. Zhang et al., 2003), delivery of GUSB 
enzyme in a model of MPSII (Y. Zhang et al., 2008), and with tumor size reduction and increased survival 
after delivery of interfering RNAs in a model of GBM (Y. Zhang et al., 2004b). One study even showed that 
TfR-targeted liposomes encapsulating plasmid DNA could be administrated to a pregnant mouse, cross the 
placental barrier and mediate gene expression in the developing brain of the fetus (Cornford et al., 2015). 
Furthermore, endogenous Tf was tested in several studies as a targeting molecule for liposome transport with 
a variety of therapeutic effects including improvement after stroke and brain injury (Omori et al., 2003; Suresh 
Reddy et al., 2006), increased brain uptake of HIV drugs (Prabhakar et al., 2011), tumor size reduction in GBM 
(Jhaveri et al., 2018; Lakkadwala and J. Singh, 2019; C. Liu et al., 2017; Salzano et al., 2016; Sonali et al., 
2016b; Zheng et al., 2015), or general gene knockdown after siRNA delivery into the brain (Cardoso et al., 
2010; 2008). One study used peptide-based targeting of the TfR for delivery of vinblastine in a model of GBM 
(L.-M. Mu et al., 2017). The efficiency of drug transport using Tf-modified liposomes has also been improved 
by co-attachment of different cell-penetrating peptides, e.g. TAT from HIV, which has led to major increases 
in the %ID/g that reaches the brain. In fact, some formulations could deliver in the order of 4 %ID/g, which is 
comparable or superior to what can be obtained in a non-CNS tumor model (Sharma et al., 2012; 2013; 2014; 
2016; Wilhelm et al., 2016). Still, for mono-targeted liposomes, TfR antibodies were superior to both 
endogenous Tf and other relevant targets on the endothelial surface of the BBB (van Rooy et al., 2011b), 
although others claim that only endogenous Tf-functionalized nanoparticles will transcytose as opposed to 
nanoparticles functionalized with monoclonal antibodies (Clark and Davis, 2015). The size of the liposomes 
has also been described as a major factor for determining subsequent BBB passage, where increasing sizes 
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will lead to a decrease in cargo/liposome transport (Hatakeyama et al., 2004). It is therefore up for debate, 
whether results suggesting an accumulation of 40 %ID using liposomes between 750 – 2000 nm can be 
regarded as valid (Soni et al., 2005). TfR-targeted liposomes can also be found accumulating in the lysosomes 
of BCECs, hereby suggesting that endocytosis of such large constructs would likely distort the normal 
endosomal sorting process, and instead target the endocytosed material for degradation in the lysosomes 
(Johnsen and Moos, 2016; Visser et al., 2005). Like for the OX26 antibodies alone, the possibility of liposome 
transcytosis into the brain after targeting with OX26 was questioned by Moos and colleagues, who could only 
show accumulation of liposomes in the BCECs, but not in the brain parenchyma after brain capillary depletion 
(Gosk et al., 2004; Moos and Morgan, 2001). Later, it was found that while the liposome was confined within 
the vascular fraction of the brain, an encapsulated, small molecule drug could be detected in the brain 
parenchyma (Johnsen et al., 2017). This raises the possibility that liposomes may only be able to transport the 
drug cargo to the BCECs, who are then responsible for transporting the cargo further into the brain parenchyma 
(Johnsen et al., 2017; Johnsen and Moos, 2016). Such a release mechanism still remains t  be described. 
Factors such as ligand density and dosing regimen of the TfR-targeted liposomes were also shown to impact 
the resulting brain transport (see later) (Huwyler et al., 1996; Johnsen et al., 2017; 2019; Papadia et al., 2017). 
Furthermore, the impact of different variants of anti-TfR antibodies on the resulting transport of liposomes has 
not been assessed but could be studied in detail by exploiting new developments in nanobiotechnology (Kedmi 
et al., 2018). 
 
3.4. Polymeric nanoparticles 
Another widely used way of composing a nanoparticle is based on polymers of macromolecules (Kreuter, 
2014). These polymers can be designed to infer different capabilities to the nanoparticle, e.g. controlled release 
mechanisms or encapsulation of specific drug compounds. Furthermore, they are often biodegradable within 
a short time frame, which has been suggested as a requirement for a brain drug delivery system based on 
polymers (Kreuter, 2014). The field of polymeric nanoparticles using the TfR as a target for brain drug delivery 
is not as well-established as the field of liposomes described above. Nevertheless, polymers are important in 
both strategies, since almost all studies on TfR-targeted liposomes employ a polymer coating to increase the 
circulatory properties of the formulations, e.g. the well-known polyethylene glycol (PEG). PEG itself has been 
combined with chitosan to produce nanoparticles that could deliver anti-caspase peptides to the brain using the 
OX26 antibody as a targeting molecule (Aktaş et al., 2005; Yemisci et al., 2015; 2012). OX26 has also been 
used to target both poly-lactic acid (PLA)-PEG, PEG-polycaprolactone (PCL), and poly(lactic-co-glycolic 
acid) (PLGA) nanoparticles to the brain, hereby delivering amphotecirin B, Aß peptide, temozolomide, and 
Tempol across the endothelial layer (Bommana et al., 2012; Carroll et al., 2010; Loureiro et al., 2016; Pang et 
al., 2008; Ramalho et al., 2018; Sriramoju et al., 2015; Tang et al., 2015). The anti-mouse TfR antibody 
variants, 8D3 and RI7, were also used to target polymer nanoparticles towards the brain (Bhattacharya et al., 
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2008; Papademetriou et al., 2013). PLGA and PEG nanoparticles functionalized with endogenous Tf could 
deliver nevirapine, paclitaxel, temozolomide, and methotrexate to mediate therapeutic benefit in disease 
models both in vivo and in vitro (Atul Jain et al., 2015; Aviral Jain et al., 2011; T. Kang et al., 2015; Kuo et 
al., 2011; P. Zhang et al., 2012a). Peptide- and aptamer-based targeting of PEG-PLA and PLGA nanoparticles 
was also used to enhance brain uptake (Bi et al., 2016; Falanga et al., 2018; Gomes et al., 2017; C. Mu et al., 
2013). Chitosan nanoparticles have been functionalized with several types of TfR-targeting ligands to deliver 
drugs across the BBB (Gu et al., 2017; Karatas et al., 2009; Sahin et al., 2017; Yemisci et al., 2018). Less used 
polymers include poly(β-L-malic acid) (PbMLA) for temozolomide and anti-tumor antibody fragment delivery 
(Fujita et al., 2007), polyphosphoester (PPE) micelles for paclitaxel delivery and anti-GBM activity in vivo, 
polyamidoamine (PANAM)-PEG for RNAi delivery, luciferase inhibition, and temozolomide delivery in 
models of GBM model in vivo, 3-diaminobutyric polypropylenimine dendrimer (DAB) for DNA condensation 
and delivery in vivo, and d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) micelles for 
docetaxel delivery in vivo (Agrawal et al., 2017a; 2017b; Kuang et al., 2013; Patil et al., 2010; Somani et al., 
2014; Sonali et al., 2016a; T. Sun et al., 2017; P. Zhang et al., 2012b).  A TfR-targeting peptide functionalized 
to the surface of polyanionic polymalic acid nanoconjugates in a dual-targeting setup with tre-leucine lead to 
an improve transport of rhodamine (model cargo) to the brain parenchyma (Israel et al., 2019). The brain 
uptake efficiency was, however, less consistent than what was observed for a similar nanoconjugate targeted 
to LRP1. Furthermore, camptothecin complexed in mucic acid polymer nanoparticles could be delivered to 
brain metastases of breast cancer via TfR-mediated transport facilitated by spacing the nanoparticle and Tf 
protein with an acid-cleavable linker (Wyatt and Davis, 2019). It thus seems clear that various kinds of 
polymers can mediate brain drug delivery in combination with TfR-targeting. However, this large number of 
different polymers currently employed as nanocarriers for TfR-mediated brain drug delivery highlights that 
more research is needed to validate the relevance of each type of polymer nanoparticle for use in such a drug 
delivery strategy. First, there is a great lack of studies reproducing earlier findings (maybe in a new context), 
and there is currently no head-to-head comparison of different types of polymer nanoparticles to analyze 
whether any specific type of polymer could be suited for brain drug delivery. Here, attention could be given 
to studies investigating other receptor systems for transport, as these fields may be more developed. It is also 
of special interest to compare different kinds of polymeric nanoparticles with liposomes to decipher whether 
one strategy is superior to the other. However, this will likely be context-based with variations appearing as a 
function of both the nanoparticle composition (i.e. what types of lipids and polymers and the molar ratio 
between them) and the disease in which the different strategies are compared. For a thorough review on 
polymers used for brain drug delivery, please refer to Kreuter (2014)(Kreuter, 2014). 
 
3.5. Gold nanoparticles 
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Another type of nanoparticle that offers both the possibility of delivering drugs, but also strong advantages in 
basic studies of nanoparticle behavior in the brain, is the gold nanoparticle. Gold nanoparticles are produced 
by reduction of Au salt in solution, and this procedure gives much better control over the size and 
polydispersity of the resulting nanoparticles compared to both liposomes and polymeric nanoparticles 
(Sperling et al., 2008). Gold nanoparticles can be produced in sizes down to 1.5 nm, which is well below what 
can be accomplished with other types of nanoparticles (Male et al., 2016). TfR-targeting of gold nanoparticles 
has received increased attention through the recent years, and several studies have provided interesting 
evidence on the passage of different sized particles into the brain. Initial studies on the transport capabilities 
of the OX26 antibody and Tf were performed with the use of small diameter gold nanoparticles for tracking 
(Bickel et al., 1994; van Gelder et al., 1997). Prades and colleagues functionalized gold nanoparticles (5 – 13 
nm) with a fusion peptide with the capacity of attaching to both the TfR and -amyloid (Prades et al., 2012). 
These gold nanoparticles were first administrated to a primary bovine in vitro model of the BBB, where they 
were shown to transcytose efficiently. After intraperitoneal injection into mice, the gold nanoparticles could 
also be detected in neuronal cells in the brain cortex (Prades et al., 2012). Such uptake likely has a two-faced 
explanation with contributions both from the TfR-targeting and from the small size of the gold nanoparticles. 
In fact, others have shown that gold nanoparticles of such small size can enter the brain without any targeting, 
although introduction of a targeting ligand increases the efficiency of the transport markedly (Gromnicova et 
al., 2013; 2016b; Male et al., 2016). Working with larger nanoparticles, the group of Mark E. Davis has 
presented evidence that PEGylated gold nanoparticles of around 80 nm can be transported across the BBB and 
be detected by light and electron microscopy in several regions of the brain parenchyma (Wiley et al., 2013). 
Interestingly, the transport efficiency could be increased by tuning the avidity of the targeted gold nanoparticle, 
i.e. by optimizing the number of endogenous Tf molecules present on the gold nanoparticle surface (Wiley et 
al., 2013). This concept was applicable regardless of the initial size of the gold nanoparticle (Wiley et al., 
2013). The group also showed that the gold nanoparticle could be designed to take advantage of the known 
uptake process of the TfR, where endocytosis and subsequent sorting will lead to acidification of the endosome. 
By spacing the endogenous Tf and the PEG-coating layer with a pH-sensitive linker, the authors could increase 
the transport of gold nanoparticles into the brain, likely because the presence of a pH-sensitive linker allowed 
for dissociation of the gold nanoparticle from the endocytosed receptor (Clark and Davis, 2015). However, 
this was only true, when the gold nanoparticles were functionalized with endogenous Tf compared to a TfR 
antibody. This again points towards the fact that binding to a ‘wrong’ part of the TfR may distort the 
intracellular sorting after endocytosis, thus, targeting the material directly for degradation in the lysosomes 
(Clark and Davis, 2015). Along with this, it was recently shown that gold nanoparticles functionalized with 
different variants of anti-TfR antibodies were transported differently across the BBB (Johnsen et al., 2018). In 
particular, an antibody binding the TfR with only one of its two variable domains made significant 
improvements to the transport efficacy, underscoring the findings of previous studies that monovalent binding 
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of either antibodies or endogenous Tf protein to the TfR is favorable for brain transport (Clark and Davis, 
2015; Johnsen et al., 2019; 2018; Wiley et al., 2013). Smaller gold nanoparticles have also been attached to Tf 
peptides and dual-targeted by co-attaching EGF peptide to obtain both transfer capabilities across the BBB 
and accumulation properties in GBM tumors (Dixit et al., 2015a; 2015b). 
Gold nanoparticles may not necessarily be the best choice for brain drug delivery since the drug 
loading capacity is well below that of a liposome or a polymeric nanoparticle. However, the gold nanoparticles 
are due to their composition, chemical properties, and easily controlled production, a good model nanoparticle 
to employ in basic studies of nanoparticle behavior in tissues (Kempen et al., 2013), e.g. in the brain or in the 
process of transcytosing into it. This was nicely illustrated in an electron microscopy-based mapping of the 
endocytosis process of gold nanoparticles functionalized with the 8D3 antibody (targeting the mouse TfR) 
(Cabezón et al., 2015). These investigations revealed that the gold nanoparticles were taken up by the BCEC 
in vivo, but also that the level of transcytosis observed was very low (Cabezón et al., 2015). The picture was 
further complicated by the fact that the few gold nanoparticles that had transcytosed seemed to be stuck in the 
meshwork of the basement membrane to which the BCECs anchor, an observation that was also reported for 
other metal nanoparticles after mannitol-induced disruption of the BCEC layer (Cabezón et al., 2015; Muldoon 
et al., 1999). This is in direct opposition to the studies mentioned earlier, which showed the presence of gold 
nanoparticles associated with neuronal cells distances away from the capillary (Clark and Davis, 2015; Johnsen 
et al., 2018; Wiley et al., 2013). Even though gold nanoparticles are easily visualized with electron microscopy, 
sample preparation for this method can induce artefacts (e.g. salt crystals) that are indistinguishable from the 
real gold nanoparticles (Johnsen, 2018). It is therefore important to validate the findings by doing elemental 
composition analysis on the area of interest using energy-dispersive X-ray spectroscopy (Johnsen, 2018), 
especially when indicating transcytosis based on observations of gold nanoparticles in parenchymal structures 
like neural processes (Johnsen et al., 2018). Lastly, the presence of gold nanoparticles in a tissue sample is 
also easily detectable using methods like inductively-coupled plasma-mass spectrometry (ICP-MS), whereby 
quantitative data on the whole nanoparticle in a tissue fraction (and not just a cargo) can be obtained (Johnsen 
et al., 2019; 2018; Male et al., 2016). These factors represent a major advantage in the studies on the transport 
of nanoparticles into the brain. 
 
3.6. Miscellaneous nanoparticles 
The nanoparticles described above account for the clear majority of studies currently published using the TfR 
as a target for brain drug delivery. However, other (and less well known) kinds of nanoparticles have also been 
tested in this context. For example, carbon dots attached to endogenous Tf could be transported into human 
brain tumor cells and the brains of zebrafish, the lowest species known to have a functional BBB (L. Li et al., 
2016; S. Li et al., 2016). Quantum rods attached to endogenous Tf could deliver saquinavir in a model of 
neuroAIDS, whereas attachment of quantum dots to RI7217 antibodies underscored the fact that no 
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transcytosis is taking place for these kinds of strongly binding antibodies (Mahajan et al., 2010; Paris-Robidas 
et al., 2016). RI7217 binds to the mouse TfR with a KD = 6 nM (Johnsen et al., 2018). PEGylated graphene 
oxide nanoparticles functionalized with Tf delivered doxorubicin and improved the treatment outcome in a 
model of GBM (G. Liu et al., 2013). Ferritin nanocages were found to transport across the BBB to deliver 
therapeutic cargo in several models of GBM, and their transport was hypothesized to be dependent on binding 
to TfRs (Chen et al., 2017; Fan et al., 2018; Zhai et al., 2018). This hypothesis was recently validated in a 
study showing transcytosis of ferritin as a means of transporting iron atoms from the blood to the brain (Chiou 
et al., 2018a; Chiou and Connor, 2018), and the structure of the ferritin-TfR complex was recently published 
(Montemiglio et al., 2019). Magnetic nanoparticles either free or encapsulated in liposomes also benefit from 
being functionalized with endogenous Tf (Ding et al., 2014; Yan et al., 2013). One study showed that even 
though external magnetic force was applied to a specific area, the system still needed the TfR targeting for the 
magnetic nanoparticles to move across the BBB (Ding et al., 2014; Yan et al., 2013). Another study 
functionalized polymer nanoparticles with small magnetic nanoparticles and OX26 antibodies, and found this 
to be beneficial for cellular uptake in SHSY-5Y cells (N. Cui et al., 2018). Albumin nanoparticles targeted 
towards the TfR either with OX26 or RI7217 antibodies could mediate improved anti-nociceptive effects of 
loperamide in mice (Ulbrich et al., 2009). That such effects can be mediated in mice using OX26 as a targeting 
molecule with equal efficiency to RI7217 is, however, perplexing (Boado et al., 2009). OX26 was raised in 
the mouse against the rat TfR, it binds only weakly to the mouse variant with a KD = 16 µM, and OX26 
immunoliposomes associate only very slightly to bEnd.3 cells in vitro (Johnsen et al., 2018; 2017). Suicide 
gene delivery via phage nanoparticles was used to reduce the volume of intracranial xenograft tumors after 
targeting with iron mimic peptides that could exploit the normal sorting pathway of the TfR (Staquicini et al., 
2011). In addition, mesoporous silica nanoparticles endowed with Tf on their surfaces could traverse the BBB 
both in vitro and in vivo (in zebrafish and mice) (Heggannavar et al., 2018; Yang et al., 2016). Finally, different 
types of lipoprotein particles (including LDL and HDL) has been functionalized with TfR-targeting peptides 
to increase the uptake of therapeutic cargo (including vincristine and camptothecin) in C6 rat xenograft GBM 
tumors established in mice (L. Cui et al., 2018; Liang et al., 2018). 
 
4. Challenges for current TfR drug delivery strategies 
 
4.1. Does the TfR transcytose drugs into the brain? 
Regardless of the disagreement on whether a TfR-targeted drug delivery system will transcytose through the 
BBB, the vast amount of data showing a preclinical therapeutic efficacy benefit suggest that in some form the 
TfR is a good choice for transporting drugs into the brain parenchyma. However, claiming that any therapeutic 
effects are obtained by transcytosing the TfR with a drug is still controversial. As described previously, the 
overwhelming evidence on the physiological dynamics of the TfR in brain iron uptake suggests endocytosis 
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of the receptor, followed by a dissociation of iron from the Tf-TfR complex (Burkhart et al., 2016; Duck and 
Connor, 2016; Hersom et al., 2016; Skjørringe et al., 2015). In relation to this, one could ask the question: 
Why would the endothelial cells of the brain have developed an iron uptake mechanism (i.e. transcytosis) so 
different compared to other cells, especially those also composing a biological membrane such as the epithelial 
lining of the gut? What would have been the evolutionary driver?  
Recently, the TfR was detected on the abluminal membrane of the BCECs in vivo, but these findings 
were interpreted in the context that BCECs can act as a reservoir and regulator of iron uptake and clearance in 
the brain (Simpson et al., 2015). This means that by expressing TfRs on the abluminal membrane, the BCEC 
could ‘sense’ the intraparenchymal iron status and regulate the recycling rate of TfRs on the luminal membrane 
to either increase or decrease iron-Tf uptake from the blood (Simpson et al., 2015). Some have reported that 
gold nanoparticles injected into the bloodstream in rare cases can be observed on the abluminal membrane of 
the BCECs, suggesting the transcytosis mechanism to be possible, but also very rare (Cabezón et al., 2015; 
2017; Johnsen et al., 2018), while others show this route to be rather efficient for entry of TfR-targeted gold 
nanoparticles (Clark and Davis, 2015; Wiley et al., 2013). Additional controversies exist between those 
reporting TfR antibodies to pass the BBB, and those reporting the same antibodies to remain confined in the 
capillary wall (Friden et al., 1991; Moos and Morgan, 2001; Pardridge et al., 1991), but recent advances in 
antibody technology indicate that the route could indeed be feasible (Bien-Ly et al., 2014; Niewoehner et al., 
2014; Sade et al., 2014; Yu et al., 2014; 2011). Although promising, the safety profile of these newer constructs 
is detrimental to further clinical development, turning some towards looking for new targets on the BBB for 
drug transport (Couch et al., 2013; Zuchero et al., 2016). With regards to the transport of nanocarriers into the 
brain to deliver a therapeutically active molecule (e.g. plasmid DNA), some report that expression of the 
encapsulated gene product can be detected in most areas of the brain after intravenous injection, hereby 
claiming that the whole nanoparticle and cargo is effectively transcytosed through the BBB (Shi et al., 2001b; 
Shi and Pardridge, 2000). Others, however, claim that the route of entry might as well have been the choroid 
plexus, which is also rich in TfR expression (Lichota et al., 2010). It could also be that the nanoparticle was 
processed in the BCEC yielding the cargo DNA product in its free form to be exported into the brain 
parenchyma. 
There is still no consensus both with respect to the transcytosis and drug delivery potential of the TfR. 
Nevertheless, the evidence presented in the recent years on how to improve the technology by incorporating 
important aspects of the receptor sorting into the drug construct/nanocarrier design has made very encouraging 
contributions to the field, which hopefully will spark both further drug development and basic research in the 
receptor (these improvements will be discussed later in this review). 
 
4.2. TfR-targeted brain drug delivery in disorders with loss of blood-brain barrier integrity 
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An important aspect to take into consideration when designing drug delivery system like those targeting the 
TfR is whether such active targeting of the drug provides any additional benefit compared to a non-targeted 
variant. Also, will the disease process and the potential concomitant disruption of the BBB be so severe that 
the drug will accumulate in the brain regardless of a targeting molecule? The choice of using the TfR as a 
targeting molecule is mainly due to its exclusive expression on the surface of the BBB, but this does not 
necessarily work as an argument for using active targeting in diseases with increased vascular permeability 
(Park, 2017). TfRs are also expressed by some cell types of the brain parenchyma (e.g. neurons), and therefore, 
using the TfR as a target may facilitate accumulation of the drug or nanocarriers in the area of disease if the 
BBB integrity is disrupted (Moos, 1996; Moos et al., 2007; Skjørringe et al., 2015). Many diseases of the brain 
have been characterized with a component of BBB disruption as a part of the pathophysiological process 
(Montagne et al., 2015; Turjeman et al., 2015; Zlokovic, 2008). This leads to leakage of blood constituents or 
injected probes in the areas of disease, such as a site in the brain with ongoing neuroinflammation, and these 
molecules will likely diffuse in the brain extracellular space as a function of its size (Carvey et al., 2009; 2005; 
Desai Bradaric et al., 2012; Desai et al., 2007; 2009; A. Patel et al., 2011). The impact of these 
neurodegeneration-related BBB disruptions on brain drug delivery has only been characterized systematically 
in a few studies (Avnir et al., 2011; Bien-Ly et al., 2015; Kizelsztein et al., 2009; Schmidt et al., 2003; 
Turjeman et al., 2015). For example, active targeting (with ApoE and -amyloid peptides) on liposomes were 
shown not to confer additional therapeutic effects after injection into mice suffering from the induced model 
of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), suggesting a severe breakdown of 
the BBB integrity in this model, since the liposomes could easily accumulate in the area of disease (Avnir et 
al., 2011; Kizelsztein et al., 2009; Schmidt et al., 2003; Turjeman et al., 2015). However, this model is in many 
ways extreme compared to the evidence on neuroinflammatory disorders in other models and in human disease, 
and hence, others have used this model as a positive control for BBB disruption (Bien-Ly et al., 2015). In line 
with this, recent evidence indicates that the widely accepted fact of widespread BBB disruption in 
neurodegenerative disorders must be challenged (Alata et al., 2015; Bien-Ly et al., 2015; Z. Cheng et al., 2010; 
Do et al., 2014; Minh Do et al., 2015; St-Amour et al., 2013). The results of one study showed that the size-
related cut-off on any potential BBB disruption was below 3 kDa, and that only antibodies (150 kDa) targeting 
the TfR with low affinity, as compared to non-targeting antibodies, could pass into the brain in several different 
preclinical models of Alzheimer’s disease (Bien-Ly et al., 2015). Others showed no additional transport of a 
panel of small molecule drugs (266 – 720 Da, varying transport mechanisms) in preclinical models of both 
multiple sclerosis and Alzheimer’s disease (Z. Cheng et al., 2010). However, if existing, BBB disruption may 
in fact be detrimental to drug delivery, because the structural changes in the NVU and the associated 
aberrations in perivascular and brain extracellular fluid dynamics may halt the diffusion of drugs from the 
capillary to the brain parenchyma (Sweeney et al., 2018). Thus, there is a strong argument for the continuous 
development of BBB-penetrating drug delivery strategies. 
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 Another important questions in relation to the possible disease-associated changes to the integrity of 
the BBB, is whether or not the TfR expression is modulated in disease states. In the 1990s, several groups 
showed changes in the expression of the TfR both in Parkinson’s (Faucheux et al., 1997; 1993; C. M. Morris 
et al., 1994b) or Alzheimer’s disease (Kalaria et al., 1992; C. M. Morris et al., 1994a) using autoradiography 
on post-mortem human brain specimens. While these estimations often came with large regional difference, 
e.g. between the hippocampus and frontal cortex in Alzheimer’s disease, they were rarely reflected at the 
capillary level (Kalaria et al., 1992), suggesting the TfR expression to be maintained in this compartment in 
neurodegenerative diseases. Recent studies have validated these findings by quantifying the TfR protein 
content of whole brain and capillary samples derived from transgenic mice or patients suffering from 
Alzheimer’s disease (Bien-Ly et al., 2015; Bourassa et al., 2019). Others found the TfR to be at least partially 
functional after several hours of brain ischemia (Hao and Bickel, 2013). Although some questions related to 
the expression of TfR in disease states still needs to be answered, our current knowledge suggest that it remains 
expressed and is readily available for targeting and transporting drugs to the brain parenchyma. 
 
4.3. Challenges in addition to transcytosis of the blood-brain barrier 
After having traversed the BBB, the transcytosed drug construct or nanocarrier needs to be transported to the 
area of disease, which would likely be neurons in the tissue surrounding the capillary. Circumventing the BBB 
by forcing it open can allow for the transport of nanoparticles into the brain parenchyma and can thus function 
as a model for what will happen after transcytosis (Åslund et al., 2015; Muldoon et al., 1999). The results of 
such studies are, however, very discouraging. For example, nanoparticles in size ranges suitable for high drug 
encapsulation (approximately 100 nm) seems to become stuck in the protein meshwork of the basement 
membrane located beneath the BCECs (Muldoon et al., 1999; Cabezón et al., 2015). The pore sizes of this 
basement membrane are much smaller than what would be needed for a nanoparticle to move into proximity 
of diseased neurons in the brain parenchyma, thus questioning the idea that whole nanoparticles can be 
transported into the brain parenchyma in this manner. Moreover, using pharmacokinetic modelling based on 
in vivo data, the Hammarlund-Udenaes group has proposed that the most likely outcome between a liposome 
and the BBB would be fusion with the endothelial membrane. This would in effect release an encapsulated 
cargo into the BCEC cytoplasm, wherefrom it could possibly be redistributed to the brain parenchyma for 
therapeutic action (Lindqvist et al., 2016). This will of course not be the case for non-lipid nanoparticles, but 
it does shed light on the possibility that whole nanoparticle transport across the BBB is not to be expected 
(Freskgård and Urich, 2017; Gosk et al., 2004), even though this is claimed in several studies (Zensi et al., 
2009; 2010; Wiley et al., 2013; Clark and Davis, 2015; Johnsen et al., 2018). The lipid composition of 
liposomes may also affect the cargo uptake, suggesting that unsaturated liposomes are more likely to release 
the encapsulated cargo to be transported into the brain extracellular space (Hu et al., 2017), whereas in some 
cases, liposomal encapsulation may be detrimental to the brain uptake (Hu et al., 2018). Target occupation 
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time and saturation of the encapsulated drug towards its therapeutic target is also of great importance when 
determining the effect of a liposomal brain drug delivery system (de Witte et al., 2018). Furthermore, there is 
disagreement as to the possible size of the brain extracellular space, and whether that would allow for 
movement of nanoparticles (Nance et al., 2012; Thorne and Nicholson, 2006). While most agree that proteins 
including antibodies will be able to move freely in the brain extracellular space (Pizzo et al., 2018; Plog et al., 
2018), some measurements suggest this space to be between 38 – 64 nm (Thorne and Nicholson, 2006), which 
is well below the size of most nanoparticles used for drug delivery (Johnsen and Moos, 2016). Therefore, based 
on these results, a nanoparticle strategy for brain drug delivery would not be adequate for having the drug 
compound widely distributed in the brain parenchyma (Thorne and Nicholson, 2006; Wolak et al., 2015; 
Wolak and Thorne, 2013). Conversely, others have found that a large fraction of the brain extracellular space 
has pore sizes above 100 nm, which would allow for nanoparticles to distribute, although this distribution is 
highly affected by the amount of surface coating (PEGylation) of the nanoparticles (Nance et al., 2014b; 2012; 
Suk et al., 2016). This was also the case after forced opening of the BBB (Nance et al., 2014a; C. Zhang et al., 
2017a; 2017b). Yet others have proposed that albumin nanoparticles of more than 200 nm in diameter can be 
efficiently transcytosed (although not as a result of TfR targeting) and distributed in the astrocytic processes 
to neurons distant from the capillary (Begley, 2012; Zensi et al., 2010; 2009).  
A related challenge is also facing the TfR-targeted antibodies and especially nanoparticles even before 
they have been taken up into the BCEC, namely the impact of the glycocalyx (Hempel et al., 2016; Kutuzov 
et al., 2018). The glycocalyx is a carbohydrate-rich matrix lining the luminal surface of endothelial cells, which 
gives both structural support to maintain the integrity of the endothelial cell lining, and contributes to the net 
negative charge of the endothelial surface (Hempel et al., 2016; Santos et al., 1995). Due to the negative charge 
of the glycocalyx, and the fact that it spaces the cell membrane and drug construct or nanoparticle with 0.5 – 
11 µm, it has been hypothesized to impact greatly on the uptake of nanoparticles into the brain (Gromnicova 
et al., 2016a). This would in effect mean that the TfRs on the BCEC surface are buried in the proteoglycan 
matrix, and that binding to it will be dependent on the size of the construct. In line with this, the glycocalyx 
was recently found to be a significant diffusion barrier even to low molecular weight fluorophores (Kutuzov 
et al., 2018). In rat fat pad endothelial cells, PEGylated gold nanoparticles had an overall low uptake under 
normal conditions, but this uptake was increased markedly as a response to modulations of the glycocalyx 
including collapsing and enzymatic degradation (M. J. Cheng et al., 2016). This suggested that negatively 
charged nanoparticles have a restricted interaction with the endothelial cell (and subsequent low uptake) due 
to the repulsive force of the negatively charged glycocalyx (M. J. Cheng et al., 2016). Gold nanoparticles with 
a positively charged (aminated) PEG layer interact readily with the cell surface of endothelial cells from either 
kidney or brain (Gromnicova et al., 2016a). Enzymatic degradation of the glycocalyx did, however, not change 
the uptake of these positively charged nanoparticles into BCECs significantly (Gromnicova et al., 2016a). 
Conversely, the uptake of both carboxylated and aminated polystyrene nanoparticles into human umbilical 
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vein endothelial cells was significantly improved after enzymatic degradation of the glycocalyx, suggesting 
that the glycocalyx constitutes a significant barrier for nanoparticle uptake into endothelial cells in general 
(Möckl et al., 2017). At the moment, no data exist to predict how the glycocalyx may interfere with the 
association between TfR-targeted nanoparticles and the BCEC surface, although inspiration may be taken from 
computer simulations of the interaction between intercellular adhesion molecule 1 (ICAM-1) antibody-
functionalized PLGA nanoparticles and vascular endothelium (J. Liu et al., 2010). These investigations 
indicate that the glycocalyx reduces the binding affinity of the antibody-functionalized nanoparticles (J. Liu et 
al., 2010), which may also be expected for TfR-targeted nanoparticles interacting with the brain endothelium. 
It thus seems that the impact of the glycocalyx is an important aspect to consider when designing TfR-targeted 
medicines and predicting their interaction with the surface of the BCECs. 
When the TfR-targeted drug has reached the brain parenchyma, its retention in this compartment is 
directly related to its binding properties to intraparenchymal targets. This can been investigated by creating 
bispecific antibodies targeting both the TfR and another protein either related to a specific cell type or an 
ongoing disease (Sehlin et al., 2016). For example, researchers from Uppsala University created different 
formats of a bispecific antibody capable of targeting both the TfR and ß-amyloid and showed long antibody 
retention in brains of transgenic mice that carried large loads of ß-amyloid plaques, but no antibody retention 
when the same bispecific antibody was administered to wild-type mice or transgenic mice with α-synuclein 
aggregates (Hultqvist et al., 2017; Sehlin et al., 2016; Syvänen et al., 2017). With proper intraparenchymal 
targets, the half-life of antibodies in the brain is thought to be more than a month (Bard et al., 2012; St-Amour 
et al., 2013). Others have suggested that having a intraparenchymal target is more important that the TfR-
mediated transport across the BBB, since brain retention could be achieved over several weeks after treatment 
with an antibody targeting the myelin oligodendrocyte glycoprotein (MOG) (Nakano et al., 2019). It thus 
seems to be of great importance to be clear about the aim of any future brain drug delivery study, since only 
evaluating the transport module (the anti-TfR part) will be highly dependent on the time point of analysis due 
to the relatively fast clearance from the parenchymal compartment when retention cannot be ensured by an 
intraparenchymal target, whereas the ability to target a protein present in the brain parenchyma will change 
this rate of clearance (and therefore also the measured transport efficiency across the BBB) significantly (Bard 
et al., 2012; Hultqvist et al., 2017; Sehlin et al., 2016; Syvänen et al., 2017). It should be noted, however, that 
neurons express the TfR to some extent, although the levels may be too low to function as an effective 
intraparenchymal target to ensure long-term retention (Moos, 1996; Moos et al., 2007). Furthermore, some 
suggest that human antibodies (thought to be non-targeted) are able to accumulate passively in the murine 
brain over time, leading to the build-up of therapeutically relevant concentrations of the antibodies in the brain 
parenchyma (St-Amour et al., 2013). 
  
4.4. Biodistribution properties and potential side effects 
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In recent years, there has been an increasing focus on the biodistribution, off-target accumulation, and the 
potential side effects that treatment with TfR-targeted medicines may include. Biodistribution analyses are 
mostly performed for studies of TfR-targeted nanomedicines, although with varying findings. For example, 
one group found very little uptake of TfR-targeted nanoparticles in peripheral organs compared to the brain 
(Sharma et al., 2014), whereas other groups found that most of the injected nanoparticle dose would be 
distributed to peripheral organs rather than to the brain (Hatakeyama et al., 2004; Johnsen et al., 2019; 2018; 
2017). The TfR is highly expressed both in the liver (hepatocytes and Kupffer cells)(J. P. Lu et al., 1989; Malik 
et al., 2011; Naz et al., 2012; R. Singh et al., 2016), and in the spleen (red pulp and residing macrophages)(Hunt 
et al., 1998; J. P. Lu et al., 1989; Naz et al., 2012; R. Singh et al., 2016). This suggests that these two organs 
would be a major accumulation site for TfR-targeted nanomedicines, but this has not unequivocally been 
proven. While the liver is a major accumulation site for nanomedicines in general, there seems to be no 
correlation with the TfR-targeting capabilities of the given formulation (Johnsen et al., 2019; 2018; 2017). 
Conversely, newer findings suggest that the splenic accumulation does increase with increased targeting 
capabilities towards the TfR (Johnsen et al., 2018). Whether this has any negative impact on organ function 
has not yet been assessed. Another important note to stress is the differences observed in the biodistribution 
profiles between different commonly used mouse strains, which could potentially have an impact on the 
resulting brain uptake of TfR-targeted CNS drugs as well. Such a phenomenon was recently observed for brain 
uptake of adeno-associated viruses (AAVs), where transduction of the brain tissue was observed with high 
efficiency in C57BL/6J mice, but was completely missing in Balb/cJ mice (Challis et al., 2019). The brain 
expression of TfRs in rodents is also known to vary significantly from early postnatal development (Siddappa 
et al., 2002) to adulthood (Moos et al., 2006; 1998) and old age (L.-N. Lu et al., 2017), and the Tf binding 
capacity also changes with age (Moos et al., 2006; 1998). Furthermore, the level of expression of TfR 
expression varies in different brain regions (Hill et al., 1985; Mash et al., 1990; C. M. Morris et al., 1989). 
This means that the choice of animal model may significantly impact the outcome of a drug delivery study 
both with respect to general biodistribution and regional uptake in the brain. Recently, drug tissue binding (not 
TfR-related) in the brain was also found to vary significantly in individual AD patients and matched controls, 
even between different regions of the brain (Gustafsson et al., 2019), which suggest that for TfR-targeting 
medicines to survive through clinical development, the initial efficiency must be very high. 
Studies on the general accumulation of TfR-targeted antibody-based medicines are not present to the 
same extent. Instead several groups employing TfR-targeting for antibody delivery to the brain have shown 
that treatment with anti-TfR antibodies may induce severe side effects. Couch et al. found that anti-TfR 
antibodies in addition to targeting TfRs on the surface of BCECs also targeted circulating reticulocytes (Couch 
et al., 2013; R'zik et al., 2001). This targeting led to reticulocyte destruction and acute clinical symptoms in 
the treated animals that were indicative of severe hemolysis (Couch et al., 2013). Interestingly, an older study 
reported a case of acquired iron-deficiency anemia caused by the production of auto-antibodies that 
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downregulated the expression of TfRs on the surface of erythrocyte progenitors, indicating that the potential 
side effects could be expected in humans as well (Larrick and Hyman, 1984). Complete remission of clinical 
and hematological symptoms was observed in the patient after immunosuppressive therapy (Larrick and 
Hyman, 1984). The side effects observed in mice after treatment with anti-TfR antibodies were induced by the 
retained effector function of the antibody’s Fc domain (Couch et al., 2013). By reducing the affinity of the Fc 
domain to the Fc receptor (by a mutation resulting in lack of glycosylation in the Fc domain), the same effects 
could not be elicited due to inability of inducing antibody-dependent cell-mediated cytotoxicity (ADCC), 
hereby significantly reducing the impact on the treated animals (Couch et al., 2013). Other mutations inhibiting 
the effector function, e.g. LALA-PG, was used by several groups to obtain the same effect (Lo et al., 2017; 
Weber et al., 2018a; 2018b). Recently, the N292G mutation was tested for reduction of effector function in a 
fusion construct between an anti-TfR antibody and EPO. While the effector function was successfully 
suppressed by the mutation, the plasma clearance was significantly higher compared to the wild-type protein 
after several types of administration, which was suggested to have detrimental effects on the general brain 
uptake and therapeutic efficacy (J. Sun et al., 2019). Parts of the reaction to anti-TfR antibodies with retained 
effector function was ascribed to complement-dependent pathways (Couch et al., 2013; Lo et al., 2017). Others 
found that full effector functionality of the antibody Fc domain was necessary for therapeutic efficacy against 
-amyloid plaques, but that this effector function also resulted in first infusion reactions in the treated animals 
(Weber et al., 2018a). Neutrophils were found to be a key player in the induction of such reactions (Weber et 
al., 2018b). Interestingly, these infusion reactions could be diminished by including the TfR-targeting function 
in the form of brain shuttle modules attached to the C-terminal of the therapeutic antibody. Proper effector 
function was then maintained for therapeutic efficacy within the brain, whereas it was lost when the construct’s 
anti-TfR brain shuttle modules bound circulating reticulocytes. This was hypothesized to be due to steric 
hindrance creating a stealth mode for effector function related to the TfR-binding (Weber et al., 2018a). Others 
disagree on the mere existence of systemic side effects after treatment with anti-TfR antibodies based on 
chronic studies with serial dosing over long periods of time (Pardridge, 2014; Y.-F. Zhang et al., 2003; Zhou 
et al., 2011b). However, these findings only applied when high affinity constructs were dosed in the 1 – 2 
mg/kg range (Y.-F. Zhang et al., 2003; Zhou et al., 2011b), whereas a recent study showed that doses of 10 – 
30 mg/kg led to a significant reduction of circulating reticulocytes and a subsequent low hematocrit in the 
Rhesus monkey (Pardridge et al., 2018b). In addition to these effects, micro- and astrogliosis was observed in 
the occipital cortex f the Rhesus monkeys, and mild to moderate axonal degeneration was observed in the 
sciatic nerve (Pardridge et al., 2018b). Both effects were discussed as being caused by the retained effector 
function of the anti-TfR fusion constructs (Pardridge et al., 2018b), which is in line with recent findings on the 
importance of orientation of the Fc domain (Weber et al., 2018a). Conversely, anti-human insulin receptor 
antibody-IDUA fusion constructs could be dosed weekly at 30 mg/kg in the Rhesus monkey without central 
or systemic side effects (Boado et al., 2016; 2013; 2014), and were recently tested in patients suffering from 
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MPSI (Giugliani et al., 2018; Pardridge et al., 2018a). Production of anti-drug antibodies (ADA) is increasingly 
being highlighted as a potential detrimental adverse effect of treatment with biological drugs, e.g. bispecific 
antibodies (Labrijn et al., 2019).This is, for example, associated with a significantly decreased survival after 
treatment with ipilimumab in patients suffering from metastatic melanoma (Kverneland et al., 2018), and thus, 
remain a great concern for the authorities when new biological drugs are being approved for clinical use 
(Boyman et al., 2014; Shankar et al., 2007). In the field of brain drug delivery, very little effort has been done 
to investigate, whether this is a similar problem for anti-TfR antibodies, although a recent study in mice 
revealed some increases in ADA titer after treatment with a chimeric anti-TfR antibody with or without fusion 
to SGSH (Boado et al., 2018). Therefore, future studies should investigate ADA production after treatment 
with anti-TfR antibodies to clarify whether this is a severe issue that needs to be handled. 
With respect to TfR-targeted nanocarriers, very little has been reported on possible side effects. For 
example, liposomes functionalized with Tf proteins did not induce hemolysis in vitro (Sharma et al., 2014; 
2013; 2012), whereas intravenous injection of antibody-functionalized liposomes did not result in any acute 
clinical symptoms in the treated animals (Markoutsa et al., 2014; Salvati et al., 2013; van Rooy et al., 2011b). 
Complete avoidance of side effects may, however, be dependent on the strength of coupling between the 
liposomes and antibodies. A recent study found that while antibody-functionalized gold nanoparticles could 
be administrated to animals without side effects, liposomes with similar antibody density elicited severe 
infusion reactions (Johnsen et al., 2019). This effect was hypothesized to be caused by the antibodies leaving 
the liposome membranes since these were attached hereto using the so-called post-insertion technique (Allen 
et al., 2002; Johnsen et al., 2019). Such labile characteristics are also known for other lipid-anchored molecules 
such as fluorophores (Ladokhin et al., 1995; Münter et al., 2018; Snipstad et al., 2016). Thus, nanocarrier-
associated anti-TfR antibodies may in fact be devoid of any immunostimulatory capacity, as is also known for 
tumor drug delivery with nanocarriers (Ahmed et al., 2015), suggesting them to be of relevance for future 
therapies. Furthermore, with the current knowledge on modifying the effector function of therapeutic antibody 
targeted to the brain via TfRs, such therapies also does not lack translational potential (Couch et al., 2013; 
Weber et al., 2018a). 
 
5. Modifications to existing TfR drug delivery strategies to improve brain uptake 
Much of the existing data on the use of TfR-targeting as a means for brain drug delivery suggest the concept 
to be relevant. Nevertheless, the absolute amount of drug that is transported via this route remains very small. 
This issue needs to be handled for the TfR-targeted drugs to reach the clinical stages of drug development. 
Fortunately, the recent years have seen numerous examples of how to improve the current system to increase 
drug accumulation in the brain parenchyma (for modifications of nanocarriers, see Figure 4). This has in 
particular been the case for antibody-based medicines, where drug exposure to the brain has been increased 
significantly via protein engineering of the binding mode (Figure 5). These changes to the binding mode in 
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terms of affinity, avidity, or pH-sensitivity are not mutually exclusive, nor can we at this point decide upon 
one superior strategy to improve the transport of TfR-targeted antibodies. In the next section, these different 
improvements will be summarized. 
 
5.1. Affinity 
For many years, it was a broadly accepted fact in the field of TfR-mediated brain drug delivery that to secure 
the most efficient targeting, uptake and transcytosis, the ligand needed to bind to the target with high affinity. 
This was especially evident given the large number of studies published on the utility of high affinity antibodies 
against the rat and mouse TfR, e.g. clones OX26, 8D3, and RI7 (Pardridge, 2014). To date, these ligands have 
been used in more than 100 studies on brain drug delivery. Use of high affinity antibodies against the TfR was 
shown to mediate effective transfer of drugs to the CNS (Pardridge, 2014), but studies rarely included a 
thorough analysis of the transport of the ligand or nanocarriers itself, and quantification of drug uptake in the 
brain was often based on measurements on whole brain homogenates. By investigating the localization of the 
ligand and nanocarriers both via morphological assessment and tracer quantification after brain capillary 
depletion, it was instead found that the high affinity ligands did indeed reach the BCECs, but no evidence 
could suggest that they effectively transcytosed across the BBB in vivo (Alata et al., 2014; Gosk et al., 2004; 
Moos and Morgan, 2001; Paris-Robidas et al., 2011). It therefore seemed that a strong binding modus does not 
necessarily predict successful transport across the BBB. 
With these findings in mind, the biotech company Genentech set out to investigate the issue on lack 
of transcytosis even though the BCECs were effectively targeted via the TfR. In a now highly cited paper, the 
Genentech group presented evidence that by sequential reduction of the antibody affinity against the TfR (i.e. 
several antibody clones), the transcytotic capacity improved with the amount of antibody within the brain 
parenchyma increasing from 0.2 – 0.6 %ID/g. Through morphological analyses it was also shown that while 
the high affinity variant of the antibody mainly was localized within the brain microvasculature, the low 
affinity variant exhibited a broad and pronounced distribution in the parenchyma of the cerebral cortex, hereby 
suggesting the antibodies to reach areas of potential disease processes (Figure 5)(Yu et al., 2011). While most 
evidence does not support any real transcytosis of the TfR itself, it was still suggested that the TfR could 
facilitate transcytosis of a given molecule, possibly via dissociation from the receptor in the endosomal 
compartment (Dennis and Watts, 2012; Yu et al., 2011). Subsequent studies of the intracellular sorting of the 
antibodies in the brain cortex showed a dramatic decrease in the expression level of the TfR (more than 50 % 
reduction) after administration of the high affinity variant antibodies (Bien-Ly et al., 2014). This suggested 
that upon treatment with this variant, the antibody and receptor was so tightly associated that the subsequent 
intracellular sorting directed the complex towards degradation. This was validated by strong co-localization 
between the high affinity variant and lysosomes. Conversely, there was very little change in the expression of 
the TfR after administration of the low affinity variant, which also correlated with a low degree of co-
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localization with lysosomes. Like the observations of the original study, the low affinity variant was instead 
found to accumulate in the brain parenchyma (Bien-Ly et al., 2014; Yu et al., 2011). Another group has recently 
validated the beneficial effects of reducing the binding affinity to the TfR by engineering well-known anti-
TfR antibodies (OX26 (mouse anti-rat) and 8D3 (rat anti-mouse)(Haqqani et al., 2018; Thom et al., 2018; 
Webster et al., 2017). These efforts resulted in improved transport across the BBB as well as therapeutic 
efficacy in pain models (Thom et al., 2018; Webster et al., 2017). Others insist that the affinity must be high 
to obtain efficient transport (Pardridge et al., 2018b). In addition, the concept of reducing the affinity to gain 
an increase in transcytosis does not only apply for the TfR, but was also shown for CD98hc (Zuchero et al., 
2016). The concept of reducing the binding affinity was also tested in non-human primates, showing more 
modest results compared to the original murine studies. Therefore, the authors suggested that the affinity needs 
to be finely balanced in order to firstly reach optimal BCEC uptake and secondly transcytose across the BBB 
with no TfR degradation (Yu et al., 2014). Another group validated these findings based on a panel of 
commercially available antibodies against the TfR in a pulse-chase in vitro setup of BBB passage (Sade et al., 
2014). The concept is still not elucidated to the same extent for larger nanocarriers (Figure 4), however, one 
study showed that the antibody with the highest affinity of those tested mediated the greatest level of 
transcytosis (Gregori et al., 2016). Conversely, using the antibodies originally developed by Genentech, it was 
shown that the low affinity variant anti-TfR antibody functionalized to gold nanoparticles yielded modest 
increases in the transport across the BBB both in vitro and in vivo (Johnsen et al., 2018). 
Despite having been challenged by the findings of low affinity TfR-mediated transport for efficient 
brain drug delivery, support of the high affinity strategy has not diminished completely. In fact, a range of 
studies published recently support the notion that high affinity (and bivalent) binding is crucial for therapeutic 
efficacy in the brain parenchyma. IDUA, IDS, and SGSH enzymes were delivered to the brain via TfR-
mediated transport fused to a chimeric antibody and could mediate therapeutic effects in models of MPSI, 
MPSII, and MPSIIIA, respectively (Boado et al., 2018; 2011; Zhou et al., 2012). Fusion of the chimeric 
antibody to TNF decoy receptors or EPO led therapeutic efficacy in models of stroke and Alzheimer’s disease 
(Chang et al., 2018; 2017; Sumbria et al., 2013a). The common denominator of these different constructs was 
a very high affinity of KD < 1 nM against the TfR and the fact that they were dosed at 1 – 3 mg/kg. Conversely, 
the most efficacious low affinity variants (explained above) had affinities in the range of IC50 = 111 – 588 nM 
(Bien-Ly et al., 2014; Couch et al., 2013; Yu et al., 2011) or KD = 76 – 130 nM (Thom et al., 2018; Webster 
et al., 2017) and was dosed at 20 – 30 mg/kg for therapeutic effect. Several factors can interfere with the 
effective transport, as illustrated by the fact that a KD = 270 nM resulted in the most transport in a human TfR 
knock-in mouse, whereas a KD = 37 nM was most efficient in the cynomolgus monkeys (Yu et al., 2014). The 
large difference both with respect to affinity and especially dosing is one of the main points of critique made 
against the low affinity hypothesis (Pardridge, 2014). Some suggest based on pharmacokinetic theory that the 
uptake properties of high affinity antibodies are selectively masked by the very high doses used to show the 
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improved uptake of low affinity antibodies. The TfR system will therefore become saturated when treated with 
high affinity antibodies, because the resulting plasma concentration will be many-fold higher than the KD of 
the antibodies, whereas this is not the case for the low affinity antibodies (Chang et al., 2018; Pardridge, 2014; 
Yu et al., 2011). Furthermore, there is a significant difference in the area under the plasma concentration curve, 
because the low affinity antibodies are not cleared to the same extent as those with high affinity, which 
combined with the large dose will increase the risk of off-target effects (Pardridge, 2014). The extent of off-
target effects was claimed to be less of a problem when treating with high affinity antibodies, since these can 
be dosed at approximately 1 mg/kg (Boado et al., 2018; 2011; Zhou et al., 2012). Furthermore, studies of high 
affinity anti-TfR fusion constructs in monkeys, as well as their recent introduction in clinical trials, underscores 
the fact that this strategy cannot be neglected for future TfR-mediated drug delivery to the brain (Okuyama et 
al., 2019; Pardridge et al., 2018b). 
 
5.2. Avidity 
Another approach of changing the binding mode between a ligand and the TfR is to modify the avidity of the 
antibody (Figure 5). Antibodies are characterized by two homologous arms containing a complementarity-
determining region (antigen-binding fragments, Fab) that decides the specificity of the antibody (Cohen and 
Milstein, 1967). A hinge region between the Fab fragments and the Fc domain determines the flexibility of the 
Fab fragments with respect to binding two antigens with a certain distance in between (Reth, 2013; Shaw et 
al., 2019). With optimal spacing between two antigens both antibody Fab fragments can bind to their epitopes, 
hereby creating an avidity effects, which is important for the overall affinity of the binding and the subsequent 
initiation of effector functions in immune cells (Shaw et al., 2019). For many years it has been known that 
upon engaging of the TfR with an antibody, the valency of the antibody molecule affects the subsequent 
expression and intracellular movement of the TfR (Crépin et al., 2010; Lesley et al., 1989). Whereas 
monovalent antibodies does not seem to affect neither surface expression nor degradation of the TfR, the 
opposite is true when a bivalent antibody molecule interacts with the receptor (Lesley et al., 1989). Probably, 
the reason for these findings is due to the dimerization or multimerization of TfRs mediated by the bivalent 
nature of an antibody, since it does not mimic the normal engagement of Tf with its receptor (Freskgård and 
Urich, 2017). The essence of these findings was tested by researchers from Roche in a brain drug delivery 
setting (Niewoehner et al., 2014). Two antibody constructs (‘brain shuttles’) were produced with either one or 
two Fab fragments (sFab and dFab, respectively), and tested for their capabilities of transcytosis. Since the 
sFab construct mimicked the monovalent binding of the endogenous ligand, it was found to transcytose 
efficiently across the BBB, even though it associated with the receptor protein at an epitope distant to that 
binding endogenous Tf (Niewoehner et al., 2014). Like the antibody variant with low affinity, this monovalent 
sFab construct did not co-localize to any great extent with lysosomes. Conversely, administration of the dFab 
constructs was characterized by a much faster degree of internalization into the BCECs, but the subsequent 
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intracellular sorting directed the ligand-receptor complex for degradation in lysosomes rather than for 
transcytosis. With regards to the surface expression of the TfR, no change was found after treatment with the 
sFab constructs, and upon treatment with Bafilomycin A1, the sFab fragments accumulated inside the BCECs, 
hereby showing that the expression level and recycling properties were retained for the TfR (Niewoehner et 
al., 2014). Treatment with dFab resulted in a reduction of TfR surface expression to an almost undetectable 
level, which suggests that bivalent engagement of the TfR of BCECs severely distorts the receptor function 
and sorting, and may therefore not be able to mediate any efficient uptake into the brain parenchyma (Freskgård 
and Urich, 2017; Freskgård et al., 2014; Niewoehner et al., 2014). Supporting these findings, when the low 
affinity TfR (see above) and CD98hc antibodies were converted to bi-specific antibodies also targeting the 
BACE1 enzyme, the change in avidity greatly affected the performance of the resulting constructs (Yu et al., 
2011; Zuchero et al., 2016). Other designs of monovalent binding brain shuttles were also recently described 
to transport an antibody-based -amyloid PET tracer into the brain parenchyma (Fang et al., 2019; Hultqvist 
et al., 2017; Meier et al., 2018; Sehlin et al., 2017; Syvänen et al., 2018), therapeutic peptides (Ruderisch et 
al., 2017), or therapeutic antibodies and enzymes (Denali Therapeutics, 2018; Syvänen et al., 2018). The TfR-
binding brain shuttles also served as important tools in the investigations of the pericyte influence on 
transendothelial transport and the presence of sorting tubules in BCECs (Villaseñor et al., 2016; 2017), whereas 
so-called dual variable domain and Tribody antibodies were recently explored for brain drug and PET tracer 
delivery (Karaoglu Hanzatian et al., 2018; Syvänen et al., 2017). In particular, the identification of sorting 
tubules and retrograde transporters in BCECs, their function, and their potential interplay with other 
intracellular organelles to mediate transcytosis will be highly important for the future development of BBB-
crossing medicines (Siupka et al., 2017; Villaseñor et al., 2017; 2018). As for the affinity strategy, dosing is 
also of great importance when determining the value of mono- and bivalently binding anti-TfR antibodies, 
because the TfR system can become saturated upon administration of large quantities of the drug (Watts and 
Dennis, 2013; Yu et al., 2011). Trace dosing can be employed to avoid this saturation, which has yielded 
impressive levels of transport (2 – 3 %ID/g) after few hours (Hultqvist et al., 2017; Sumbria et al., 2013b; 
Watts and Dennis, 2013). However, such small doses may overestimate the efficiency of the system and the 
resulting level of transport cannot directly be translated to therapeutic efficacy, because this would require 
much larger doses (Syvänen et al., 2018; Watts and Dennis, 2013). 
With respect to the delivery of large nanocarriers across the BBB, the concept of modulating the 
avidity to the TfR has also been tested (Figure 4) (Clark and Davis, 2015; Huwyler et al., 1996; Wiley et al., 
2013). The first indications of the avidity influencing the transport properties of TfR-targeted nanoparticles 
came in the seminal paper by Huwyler et al., who found that by increasing the ligand-to-surface ratio on 
PEGylated liposomes the resulting uptake into the brain changed. The increase in ligand density improved the 
brain uptake up to 29 antibodies per liposome, whereas higher densities (in this case 197) dramatically 
decreased the brain uptake (Huwyler et al., 1996). These primary observations were years later validated in a 
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study using gold nanoparticles functionalized with Tf on their surfaces. PEGylated gold nanoparticles of 
different sizes were functionalized with Tf at different surface densities and investigated for their uptake profile 
into the brain parenchyma (Wiley et al., 2013). As for the liposomes, an increase in surface density of Tf on 
the gold nanoparticles lead to higher uptake into the brain. In fact, when measuring the bulk gold content in 
whole brain homogenates, a surface density as high as 200 Tf molecules per 80 nm gold nanoparticles lead to 
a significantly higher gold content (Wiley et al., 2013). However, morphological analysis of the brain section 
revealed that even though high surface densities could transport large amounts of nanoparticles to the brain, 
most of the nanoparticles were unable to traverse the BBB, and hence they were restricted to the vessel wall 
(Clark and Davis, 2015; Wiley et al., 2013). Therefore, it seems that for nanoparticles to be able to pass the 
healthy BBB, the avidity needs to be finely tuned to reach the highest possible efficiency (Clark and Davis, 
2015; Huwyler et al., 1996; Johnsen et al., 2019; Wiley et al., 2013). Too low a surface density of the ligand 
would likely cause fewer nanoparticles to interact with the TfR on the vessel wall (Johnsen et al., 2019), 
whereas too high a surface density could distort the subsequent transport of the nanoparticle across the BCEC 
because of simultaneous engagement of too many receptors at the time (see above)(Wiley et al., 2013). 
Recently, the transport capabilities of different anti-TfR antibodies functionalized to the surface of gold 
nanoparticles were compared (Johnsen et al., 2018; Yu et al., 2011). Following the notion that avidity is an 
important determinant in subsequent intracellular sorting and transport across the BBB, it was found that gold 
nanoparticles functionalized with a bivalently binding antibody had only little brain penetrance (Johnsen et al., 
2018). This low penetrance was true even when modifying the absolute number of antibodies per nanoparticle 
(Johnsen et al., 2019). Conversely, gold nanoparticles functionalized with a bi-specific antibody binding the 
TfR monovalently were transported to the brain parenchyma with much higher efficiency, albeit still with a 
low absolute brain accumulation (Johnsen et al., 2018). Furthermore, these gold nanoparticles could also be 
detected in neural processes using electron microscopy, hereby underscoring their transcytosis potential 
(Johnsen et al., 2018). While this concept of tuning binding avidity of the nanoparticles still needs to be 
validated with more studies, some suggest that the idea of having a nanoparticle with multiple targeting ligands 
on its surface is severely flawed, i.e. simultaneous engagement of only a few receptors would be enough for 
the subsequent sorting route to be distorted, and hence, any nanoparticle that attaches to the capillary wall of 
the brain vasculature would not be endocytosed. If it did, it would most likely be targeted for destruction in 
the lysosomes (Freskgård and Urich, 2017). 
 
5.3. pH 
After endocytosis of the TfR, the endocytosed vesicle is sorted towards an endosomal compartment, which 
subsequently is acidified to induce iron release (Skjørringe et al., 2015). The iron release is thought to be driven 
by a reduction in the affinity of Tf to the iron after lowering the pH (Skjørringe et al., 2015). This implies that 
a pH-sensitive drug delivery system (Figure 5) could be a relevant strategy to employ, especially for Tf-
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conjugated drugs, but it does not necessarily imply that ligands like antibodies would detach easily, since the 
primary incident during endosomal acidification is iron release, not protein release per se (Sade et al., 2014). 
However, iron release is not the only effect of endosomal acidification after TfR internalization. Studies of the 
crystal structure of the TfR have revealed that lowering of the pH leads to significant conformational changes 
in the receptor protein structure, which could have an impact on antibodies (or other ligands) binding to the 
receptor at these locations (Eckenroth et al., 2011; Lawrence et al., 1999; Steere et al., 2012).  
A panel of different TfR antibodies were tested for their ability to cross an in vitro model of the BBB 
in a pulse-chase setup (Sade et al., 2014). While some differences in the transport potential could be explained 
by differences in the antibody affinity for the TfR, this characteristic could not account for all differences. 
Interestingly, even though two antibodies had the same binding affinity, their resulting passage properties were 
not equal. Instead, the observed differences were due to a difference in the pH-sensitivity of the binding mode. 
A pH-insensitive variant would likely show strong binding and high uptake but with a subsequent intracellular 
sorting directed for degradation, whereas a pH-sensitive variant would be associated with late endosomes and 
a higher degree of transcytosis (Sade et al., 2014). Thus, these data suggest that ligands could be modified to 
become activated during endosomal acidification, which would allow for subsequent intracellular sorting 
directed for transcytosis rather than degradation. A method to modulate the ligand to have pH-sensitivity could 
be to target it to areas of the TfR protein known to change its conformation during endosomal acidification, 
including histidine residues in the complementarity-determining region of an antibody, or to induce 
conformational changes in the antibody molecule itself, as was recently evidenced for heparin-sulfate 
proteoglycan-targeting (Eckenroth et al., 2011; Kim et al., 2016; Sade et al., 2014). Single-chain variable 
fragments against the TfR were also modified to become pH-sensitive, which made significant changes to the 
resulting intracellular sorting, although despite being interpreted in relation to BBB transport, all studies were 
performed in breast cancer cells (Tillotson et al., 2015). The pH-sensitivity can also be added as a design 
feature of nanocarriers, e.g. as a chemically reactive group between the ligand and nanoparticles (Figure 4). 
This construct enabled nanoparticle release from the receptor-ligand complex and induced transcytosis with 
subsequent distribution of the gold nanoparticles within the brain parenchyma (Clark and Davis, 2015). 
Recently, the same chemical linker was found to be beneficial for the delivery of mucic acid polymer 
nanoparticles in a model of breast cancer-derived brain metastases (Wyatt and Davis, 2019). Inclusion of the 
important aspect of acidification during TfR sorting in the design of targeted drug constructs or nanoparticles 
therefore seems very relevant. The idea could possibly be expanded to include pH-based degradation of the 
nanoparticle resulting in drug release inside the endothelial cell followed by drug transport into the brain 
parenchyma by the endothelial cell. 
 
5.4. Cell-penetrating peptides 
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Despite the different modifications that can be made to improve the capacity of TfR-targeting antibodies and 
nanocarriers, drug uptake into the brain via the TfR may only occur at very low efficiency (< 1 %ID/g)(Johnsen 
and Moos, 2016). This is likely due to the physiological receptor dynamics, and therefore this uptake can be 
very difficult to improve substantially. One possible solution can be to include passive uptake mechanisms 
using cationic moieties such as lipids or cell-penetrating peptides (Figure 4). Several studies include cationic 
lipids in the formulation of liposomes, which is useful for encapsulation of nucleic acids, but these lipids may 
also have an added uptake effect due to the strong electrostatic interaction between the cationic lipid and the 
cell membrane (Cardoso et al., 2010; 2008; Y. Zhang et al., 2004b; 2003b; 2003a). Another approach to obtain 
this kind of passive uptake in the TfR-targeted system is to add cell-penetrating peptides on the surface of a 
nanoparticle (Sharma et al., 2014; 2013; 2012; 2016). Liposomes targeted towards to the TfR using 
endogenous Tf were found to be superior to poly-L-arginine liposomes with respect to passing an in vitro 
model of the BBB. However, combining the two types of targeting improved the BBB passage significantly 
(Sharma et al., 2012). In vivo, the same liposomes could also effectively accumulate in the brain with high 
efficiency (approximately 4 %ID/g) and mediate expression of  ß-galactosidase in the brain parenchyma 
(Sharma et al., 2013). Furthermore, the same effects could also be obtained using other kinds of cell-
penetrating peptides, most prominently for the HIV-peptide, TAT (Sharma et al., 2016; 2014). Using chitosan-
based polymer nanoparticles or inclusion of other types of cationic moieties in polymer nanoparticle 
formulations can also facilitate this unspecific interaction between the nanocarriers and the cell membrane 
(Aktaş et al., 2005; Kuo et al., 2011; Yemisci et al., 2015; 2012). Additional active targeting of nanocarriers 
together with TfR-targeting is an interesting approach for obtaining better BBB penetrance of the carried drug. 
However, our understanding of the uptake mechanism has numerous gaps. For example, we do not know at 
which stage in the uptake process the cationic charge comes into play, i.e. whether the interaction happens 
already at the luminal membrane (the most likely site), or whether the charge is somehow shielded until the 
endocytosis into the BCEC has completed. The cationic nature of such nanoparticles may also reduce its 
clinical relevance in several ways, including reduced circulatory properties, unspecific uptake in other organs 
and toxicity, because of the chemical properties of e.g. a cationic lipid (Allen and Cullis, 2013). Still, it may 
be possible to optimize the design of the resulting cationic liposome to improve its clinical relevance (Heyes 
et al., 2005; Semple et al., 2010). From the biodistribution data presented for the liposomal formulation 
mentioned above, it seems that the increase in uptake observed for the brain using cell-penetrating peptides 
correlates with an overall higher uptake in the peripheral organs, which may be problematic with respect to 
the risk of side effects and low bioavailability in the blood compartment (Sharma et al., 2014; 2013). 
 
5.5. Degradation or activation of nanoparticles 
In relation to the additional targeting mediated by cationic modification of nanoparticles mentioned above, 
such dual targeting or drug release may also be achieved in a controlled manner by activation of the 
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nanoparticle at the site of interest, i.e. at the BBB (Figure 4). Such modifications are well-known for 
nanoparticles designed for use in non-CNS diseases such as cancer in peripheral tissues, where the 
pathophysiological changes in the microenvironment can trigger a destabilization of the nanoparticle to either 
release its drug cargo or expose an additional targeting moiety (e.g. a cell-penetrating peptide)(Gjetting et al., 
2014; Kaasgaard and Andresen, 2010; Torchilin, 2014). This would, however, demand that the nanoparticle 
would reach the area of disease for the drug to have its proper function, and as mentioned earlier, nanoparticles 
may not readily accumulate even though there may be some disruption of the BBB integrity (Bien-Ly et al., 
2015; Muldoon et al., 1999). Brain cancers may be particularly relevant, although disruptions in the blood-
tumor barrier may be heterogeneously distributed throughout the tumor tissue (Bruun et al., 2015; Humle et 
al., 2016; Lyle et al., 2016; Steeg, 2016; Sarkaria et al., 2017). In the case of brain cancer, it could also be 
relevant to design the nanoparticles to release its drug content in response to or propagate an external stimulus, 
such as ultrasound or heat stimulation (Eldridge et al., 2016; Mead et al., 2016; Nance et al., 2014a). This is 
particularly the case because the current nanoparticle formulations used in the clinic do n t have a high 
propensity to interact with and become taken up into brain tumor cells (Gudbergsson et al., 2019).  In addition, 
if the nanoparticles can transcytose through the BCEC, they will likely be restricted from moving into the 
neural tissue due to the basement membrane of the BBB (Muldoon et al., 1999; Cabezón et al., 2015). The 
drug would therefore need to be released from the transcytosed nanoparticle and itself diffuse towards the area 
of disease. Moreover, activation of the nanoparticle could be initiated inside the BCEC (Torchilin, 2014). In 
this way, the drug could be released either to be transported further into the brain by re-packaging by the 
BCEC, or function in the BCEC itself, e.g. by inducing the expression of therapeutic proteins that could be 
secreted into the brain parenchyma (Burkhart et al., 2014; 2017; 2015; Jiang et al., 2003). 
 
5.6. Administration routes 
To circumvent the obstacles imposed by the BBB, increasing attention has been devoted to the development 
of approaches to administrate the therapeutic antibodies and nanoparticles directly to the brain compartment 
(Woodworth et al., 2014; C. Zhang et al., 2017a). For example, different types of nanocarriers can be injected 
directly into the brain parenchyma and distribute in the extracellular or perivascular spaces using so-called 
convection enhanced delivery (CED), hereby covering large parts of the brain with either the nanoparticles or 
the carried cargo (Hadaczek et al., 2006; Krauze et al., 2005; MacKay et al., 2005; R. Saito et al., 2006), or 
they can be delivered to a focused area using ultrasound and microbubbles (Åslund et al., 2015; Baghirov et 
al., 2016). The gain in therapeutic efficacy was, however, not clearly observed when assessed in a brain tumor 
model (Sulheim et al., 2019). Antibodies and nanocarriers can also be administrated via the lateral ventricles 
or directly into the subarachnoid space via the cisterna magna to obtain brain distribution facilitated by the 
flow of cerebrospinal fluid (CSF)(Liao et al., 2018; A. W. J. Morris et al., 2016; Pizzo et al., 2018; Plog et al., 
2018; Samaranch et al., 2013; Yadav et al., 2017). Administration of TfR-targeted antibodies or nanocarriers 
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has not yet been attempted via these direct routes, although inspiration could be drawn to benefit the field of 
TfR-targeted brain drug delivery and the further transport and diffusion of TfR-targeted drugs in the brain 
extracellular space. 
The CSF is produced in the choroid plexus, wherefrom it passes the epithelium-covered lateral and 
third ventricles to enter the fourth ventricle via the aqueduct of Sylvius. From the fourth ventricle, it reaches 
the subarachnoid space where it (among other things) acts as a buoyancy fluid that covers the brain, in addition 
to reaching into the brain cortex alongside penetrating vessels (i.e. the perivascular spaces)(Bakker et al., 
2016). There is still a lack of agreement on matters such as terminology regarding the peri- and paravascular 
spaces, the direction of the CSF flow in these spaces, and the extent and types of exchange between the CSF 
and the brain interstitial fluid. Some argue for the so-called glymphatic hypothesis (Iliff et al., 2012; Xie et al., 
2013), whereas some disagree on matters regarding the direction of the peri- and paravascular flow proposed 
in this model (Bakker et al., 2016; Bedussi et al., 2017). Others propose these spaces to be identical (Bedussi 
et al., 2017). Furthermore, the validity of the glymphatic system as a model for movement of fluid through the 
brain is also highly disputed (Abbott et al., 2018; Ma et al., 2019). Nevertheless, it seems clear that compounds 
administrated into the CSF are expected to reach the subarachnoid space and (to some degree) penetrate the 
brain cortex alongside the leptomeningeal arteries (Abbott et al., 2018; Pizzo et al., 2018). Although these 
administration routes are more invasive than intravenous injection of the antibodies or nanoparticles, they have 
the potential of yielding much higher local drug concentrations, which may be crucial for therapeutic efficacy 
(Lilius et al., 2019; Pizzo et al., 2018; Plog et al., 2018). 
For example, focus has been given to the direct administration of antibodies or nanoparticles via CED 
into the brain parenchyma or the CSF for subsequent distribution in the respective fluid compartments (Pizzo 
et al., 2018; Plog et al., 2018; Woodworth et al., 2014; C. Zhang et al., 2017a). The most prominent result from 
several studies of CED with nanoparticles is that the distribution is mediated by transport in the perivascular 
compartment (Barua et al., 2012; Foley et al., 2012; Hadaczek et al., 2006; Krauze et al., 2005; 2006; Muldoon 
et al., 2004; Saitou et al., 2000; Salegio et al., 2014; C. Zhang et al., 2017a). In fact, the administrated 
nanoparticles seems to be sequestered in this perivascular space, mainly because the high resistance of the 
brain extracellular space favors accumulation in these less resistive compartments (Foley et al., 2012). This 
can in some instances be beneficial, e.g. when administrating an anti-angiogenic drug in liposomes for the 
treatment of brain tumors, where perivascular retention increases the local drug concentration (R. Saito et al., 
2006; 2004). However, in many cases, such perivascular retention will likely impede proper distribution of the 
nanoparticle-encapsulated drug, and hence, reduce the therapeutic efficacy of the drug delivery strategy (C. 
Zhang et al., 2017a). Conversely, more widespread distribution in the brain may be achieved via administration 
of antibodies or nanocarriers into the CSF, also known as intrathecal administration (Andersen et al., 2016; 
Yadav et al., 2017). Although this type of administration has been criticized for yielding very low drug 
concentrations of chemotherapeutic drugs (Woodworth et al., 2014), delivery of antibodies and nanocarriers 
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via this route has provided interesting evidence for its relevance (A. W. J. Morris et al., 2016; Pizzo et al., 
2018; Plog et al., 2018; Samaranch et al., 2013). For example, three recent studies used intrathecal 
administration to ensure a broad brain distribution of antibodies and antibody fragments (Lilius et al., 2019; 
Pizzo et al., 2018; Plog et al., 2018), e.g. to bind -amyloid plaques in a mouse model of Alzheimer’s disease 
(Plog et al., 2018). The most significant effect was, however, both dependent on the size of the molecule and 
co-administration of hyperosmolar concentrations of mannose (Pizzo et al., 2018; Plog et al., 2018) or 
dexmedetomidine (Lilius et al., 2019). 
Omitting the BBB completely will in principle reduce the relevance of TfR-targeting, since no 
transport across the barrier is needed. The most recent evidence on the transport of anti-TfR antibodies suggest 
that transport across the BBB can be made highly efficient (Niewoehner et al., 2014; Yu et al., 2011), and thus, 
the need for additional administration routes is little. However, the TfR is also an important target on cells of 
the brain, including neurons (Moos, 1996; Moos et al., 1998), which may illustrate a relevance of TfR-targeting 
after direct administration. Direct administrated TfR-targeted diphtheria toxin has previously progressed to 
phase III clinical trials, suggesting such administration routes to be viable and relevant (Chandramohan et al., 
2017; Laske et al., 1997; Weaver and Laske, 2003). 
 
6. Conclusion 
Drug delivery to the brain remains a severe obstacle for treatment of neurological diseases due to the hindering 
imposed by the BBB. Since the passive accumulation of therapeutically active substances is almost non-
existing, approaches utilizing targeting of BBB-associated receptor proteins have been heavily investigated 
for several decades. Amongst the different receptor systems that can be targeted, the TfR has remained the 
most important for brain drug delivery. The main advantages in targeting the TfR lies in its exclusive 
expression in brain vasculature compared to peripheral vasculature, which is thought to enable acute 
accumulation of therapeutically active molecules in the brain.  
 There is still no consensus regarding the intracellular sorting of the TfR in BCECs, especially with 
respect to its potential of being transcytosed. Most of the research field dedicated to the study of brain iron 
uptake favors a model without transcytosis, whereas the field of brain drug delivery relies on the possibility of 
transcytosis to explain their improved efficacy of TfR-targeted medicines compared to non-targeted variants. 
Therefore, it is of great importance for these two fields to converge in order to fully understand the functionality 
and sorting potential of the TfR. This will provide both basic knowledge on brain iron handling as well as 
indications on how to design efficiently transported brain drug delivery systems. The recent development of 
pH-sensitive drug delivery systems that take advantage of the intracellular sorting of the TfR is a good example 
of this. 
 Regardless of the lack of common grounds with respect to the fundamental understanding of the TfR, 
it has been used for brain drug delivery purposes for almost 30 years. The many studies have unambiguously 
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underscored its relevance as a brain drug delivery target, and some even suggest it to be superior to other 
receptor systems. This is illustrated further by the fact that the pharmaceutical and biotechnological industry 
has a great interest in studying the TfR. The interest from the industry has also paved the way for some 
significant leaps forward in our understanding of the binding mode between the TfR and a targeting ligand or 
antibody, and how this can depict the downstream uptake process, intracellular sorting, and transport into the 
brain parenchyma. As such, we now know that modulation of the binding affinity and avidity can be very 
beneficial for the transport of antibodies into the brain parenchyma, where they are able to elicit their 
therapeutic potential. Progression of these projects into clinical trials are expected very soon, and the results 
of these trials are expected with great anticipation. Nevertheless, the classical strategy of high affinity binding 
should not be neglected, since the amount of available evidence in support of this strategy is vast and the 
strategy has progressed into clinical trials. Successful development of clinically relevant TfR-targeted, 
antibody-based brain medicines will also require a larger focus on the translational aspect of interspecies 
differences in TfR expression and function. The recent introduction of human TfR knock-in animal models 
and cynomolgus monkeys by the biopharmaceutical industry in their preclinical development platforms will 
therefore likely inspire academic researchers to study this aspect more in depth in the future. Furthermore, 
additional knowledge on the impact of intraparenchymal targets on the retention of antibodies in the brain will 
likely lead us to design better studies in the future that can fully illustrate the potential of any given TfR-
targeted, antibody-based brain medicine. 
 Nanomedicine has been a great focus point for drug delivery in general, and many studies indicate 
that TfR-targeting of different kinds of nanoparticles to the brain is a feasible strategy to increase drug exposure 
in the brain. However, compared to antibody-based medicines, the field of nanomedicine has not progressed 
as far, even though initial targeting of the BCECs is very efficient via the TfR. The reasons for this may be 
many-fold, but several quantitative assessments of nanoparticle and/or cargo uptake into the brain parenchyma 
indicates that the overall transport efficiency is at least an order of magnitude lower than that for antibody-
based medicines. This is likely because of the big difference in size, and time will tell whether this efficiency 
can be increased to a stage relevant for clinical development. If not, there are multiple ways TfR-targeted 
nanomedicines could be modified in order to obtain a better drug exposure to the brain. These strategies involve 
the introduction of different types of sensitivities (e.g. towards redox potential or pH) or modes of activation, 
which would make the nanoparticle disintegrate to release its encapsulated cargo, or expose a cell-penetrating 
peptide that will enable further transport from the BCEC to the brain parenchyma. Inclusion of these strategies 
in nanomedicine will be of great importance for future studies. 
 The past decade has been enormously important for the field of TfR-mediated brain drug delivery, 
and the new inventions have sparked renewed motivation in developing this therapeutic concept further. With 
the expectation of further clinical progression very soon, the next years will be of great interest for the entire 
field of brain drug delivery.  
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Figure legends 
 
Figure 1. The structure and function of the blood-brain barrier. The blood-brain barrier (top) is composed 
of brain capillary endothelial cells (E) that line the microvessels of the brain. The structure is supported by 
pericytes (P) and astrocyte end-feet (A), which are crucial for maintaining the low permeability conditions of 
the blood-brain barrier. Paracellular transport of molecules is largely restricted due to the tight junction protein 
complexes (bottom) including claudins and occludin. These tight junctions are further strengthened by the 
binding to the cell’s actin cytoskeleton via adaptor proteins such as cingulin and the zonula occludens (ZO) 
proteins. 
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Figure 2. Transport mechanisms at the blood-brain barrier. Cells and molecules can enter the brain 
parenchyma by traversing the blood-brain barrier. As a part of the immune surveillance or during pathological 
conditions in the brain, immune cells can migrate through the endothelial cell to enter the brain parenchyma 
and exert their functions. The brain capillary endothelial cells are also characterized by the expression of 
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several transport proteins that can move nutrients such as sugars or amino acids through the cell. If the 
molecules are very small and hydrophilic, they may also be able to traverse the endothelial layer at the cell-
cell junctions. Furthermore, positively charged molecules can interact with the negatively charged cell surface 
to initiate a process known as adsorptive transcytosis. Lipophilic molecules can readily enter the intracellular 
compartment and be transported into the brain parenchyma, but many molecules with this characteristic are 
also substrates for the P-glycoprotein (P-gp), an important efflux pump. Lastly, plasma proteins can bind to 
receptors on the endothelial cell surface to initiate a process, whereby the receptor and bound molecules are 
transported through the cell. This is known as receptor-mediated transcytosis.  
 
Figure 3. Iron uptake across the blood-brain barrier. Brain iron uptake is thought to occur via one of two 
currently discussed models. The first model (left) involves endocytosis of the Tf-TfR complex followed by 
acidification of the resulting endosome. The reduction in pH during the acidification reduces the affinity of the 
two iron atoms for the Tf protein, and thus, they dissociate. The ferric iron is then reduced by ferrireductases 
present in the endosome membrane (e.g. Steap proteins) to yield ferrous iron, which can be transported out of 
the endosome by DMT1. The ferrous iron can subsequently associate with the iron exporter, ferroportin, which 
can pump iron into the brain parenchyma. This process is, however, dependent on the activity of a ferroxidase 
(e.g. hephaestin or ceruloplasmin). These ferroxidases can be found both soluble and associated with the 
plasma membrane of the brain capillary endothelial cells (E), the pericytes (P), and the astrocytic end-feet (A). 
Release of protein-bound iron has also been proposed in this model, but depends on an intracellular pool of Tf 
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molecules in the BCECs rather than a transcytosis process of Tf molecules from the systemic circulation. The 
second model (right) also involves endocytosis of the Tf-TfR complex, but instead of having the iron atoms 
releasing during the endosomal acidification, the TfR itself transcytoses across the brain capillary endothelial 
cell to present the holo-Tf protein to the brain parenchyma. Subsequently, the Tf protein will be released into 
the brain parenchyma, although dissociation of the iron atoms at the abluminal membrane has been suggested. 
 
Figure 4. Modifications of nanoparticles to improve brain uptake. The efficiency of TfR-targeted 
nanomedicines may be improved by exploiting the impact of adding new features to the drug delivery system 
(here the liposome). First, varying the surface coating density may be of great importance, since this can affect 
the nanoparticle’s ability to move in the brain parenchyma after transcytosis. To obtain transcytosis, its 
targeting ligand should also be endowed with the ability of dissociating the TfR during the intracellular sorting 
process, e.g. by modulating the pH-sensitivity, affinity or avidity. The transendothelial transport may also be 
enhanced by dual-targeting the nanoparticle with a cell-penetrating peptide. The size of the nanoparticle is also 
an important aspect to consider since different sizes can initiate different kinds of intracellular sorting, where 
the one for smaller nanoparticles may be more favorable for transport across the blood-brain barrier. If the 
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nanoparticle is not expected to leave the endothelial cell after endocytosis, or if the nanoparticle is stuck in the 
basement membrane after transcytosis, designing the nanoparticle to become activated in either of these 
compartments could also be a favorable approach. One way is to incorporate stimuli-sensitive lipids into 
liposomes that make the liposome disintegrate in specific microenvironmental conditions. The same 
microenvironments could also be used as an activator for cleaving stimuli-sensitive linkers spacing the surface 
coating and the nanoparticle. 
 
Figure 5. Modifications of antibody-based medicines to improve brain uptake. Several strategies exist to 
improve the brain uptake of antibodies with a therapeutic efficacy within the brain. The most popular strategy 
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is to transport with the TfR across the blood-brain barrier with antibodies or antibody fragments that bind the 
TfR with high affinity. Conversely, reducing the affinity of the antibody may induce a more favorable route 
of intracellular sorting, wherein the anti-TfR antibody avoids being targeted to the lysosomes for degradation. 
This strategy also maintains the expression of TfRs at the BBB, which can be reduced when targeting with 
high affinity antibodies. Many of the beneficial effects of targeting the TfR with low affinity antibodies can 
also be obtained using a monovalent strategy. This strategy ensures that the anti-TfR antibodies cannot engage 
several TfRs simultaneously, which is known to be detrimental to further transport. Monovalency can be 
incorporated into the design of the therapeutic antibody either in 1) a classical bi-specific antibody format, 
where the TfR-targeting is placed in one of the variable domains, 2) a brain shuttle format, where a single 
chain antibody fragment is engineered into the therapeutic antibody via a linker, or 3) a “transport vehicle” 
format, where the TfR-binding epitope is incorporated into the Fc domain of the therapeutic antibody. The 
latter two strategies also allow for the therapeutic target to be engaged in a bivalent format. Lastly, the binding 
between the transporting antibody and the TfR can be sensitive to changes in pH, which will detach the 
antibody when the endosomal acidification takes place during TfR endocytosis and intracellular sorting. 
 
